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ABSTRACT
DESIGN, SYNTHESIS, AND EVALUATION OF GUNW-3 AS A BRAIN
TARGETING AGENT
ASIM NAJMI
2019
The blood brain barrier (BBB) is a barrier in the brain that separates the peripheral
blood circulation system from the central nerve system (CNS). The barrier effectively
protects the brain from xenobiotics. The BBB serves as a physical barrier through the
tight junction of endothelial cells that were found to be 50-100 times tighter than that of
normal endothelial cells. Different drug efflux pumps such as P-glycoproteins and
multidrug-resistance proteins are found to be overdistributed on the BBB. These drug
efflux pumps help pump xenobiotics out if they enter the cells and serv as an additional
mechanism to prevent xenobiotics from entering the CNS. The tight junction, drug efflux
pumps, and other features of the BBB prevent almost 98% of small molecules, such as
most therapeutics, and almost all large molecules such as biologics, recombinant genes
and proteins from entering the brain. The inability to reach the therapeutic concentration
caused by the barrier is often the major cause of treatment failure for brain diseases.
Although the BBB blocks foreign compounds from entering the CNS,
endogenous compounds, such as glucose, amino acids, peptides, neurotransmitters, and
glutathione (GSH), enter the CNS readily through their corresponding receptors or
transporters present in the BBB. Some of these receptors or transporters have been
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targeted for facilitating therapeutics, diagnostics, and other compounds to cross the BBB
to reach the CNS.

GSH is an endogenous three amino acid peptide. It plays various roles in the
body: as a major antioxidant, a compound that removes toxic compounds, and a
compound involved in other cellular functions. GSH crosses the BBB through a Nadependent GSH transporter. Recently, GSH transporters have been found effective in
facilitating crossing of compounds through the BBB to reach the CNS. To achieve GSH
transporter-mediated BBB crossing, GSH has been linked to a therapeutic agent (GSHDrug) to form a prodrug. The prodrug crosses the BBB by binding the GSH part to a
GSH transporter followed by internalization of the prodrug. GSH has also been linked to
polyethylene glycol (PEG) which is connected to a phospholipid (P) to form GSH-PEG-P
or polyethylene glycol connected to vitamin E to form GSH-PEG-E. GSH-PEG-P and
GSH-PEG-E have been coated on the surface of liposomes (GSH-PEGylated liposomes)
to facilitate crossing of the liposomes through the BBB using the mechanism of binding
the GSH moiety to a GSH transporter followed by internalization of the liposomes
through endocytosis or transcytosis. The GSH-PEGylated liposomes have been shown to
safely enhance the delivery to the brain by approximately 3-folds.
We have developed GUNW-3 as a GSH-transporter dependent brain targeting
agent. GUNW-3 was designed by connecting a hydrophilic GSH molecule to a
hydrophobic cholesterol molecule through a two ehthylene glycol unit linker with a hope
that the GSH part can serve as a brain-targeting structure through binding to the GSH
transporter and facilitate the entry into the brain. This dissertation describes the design,
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synthesis, and fully characterization of GUNW-3. The dissertation also describes the
ability of GUNW-3 to form micelles by itself (GUNW-3 micelles), the ability of GUNW3 micelles to cross the BBB to reach the brain, and the ability of GUNW-3 micelles to
carry a dye (DiR) to the brain. Further, the dissertation shows the ability of GUNW-3
helps guide liposomes to the brain by forming GUNW-3 liposomes and the ability of
GUNW-3 liposomes to deliver a dye (DiR) to the brain. Below is a brief description of
the findings in this dissertation.
GUNW-3 was synthesized in 4 steps from cholesterol and other commercially
available reagents. GUNW-3 was found to be relatively stable. A cytotoxicity study of
GUNW-3 revealed IC50 values of 0.65 mM and 0.47 mM for CV-1 cells (monkey kidney
cells) and NCI-H226 cells (human lung cancer cells) respectively.
GUNW-3 was found to form micelles by itself with a CMC value of 3.9 μM.
CMC is a critical micelle parameter to reflect the stability of micelles and is also a
parameter to determine if the micelles are stable enough to be used for a clinical
application. The CMC of micelles need to be in μM concentration so that the micelles are
stable enough to remain as micelles once being diluted in the blood stream. The CMC in
low μM (3.9 μM) of GUNW-3 suggests that GUNW-3 micelles can be used for a
therapeutic application. Further, the CMC of GUNW-3 is much lower than the IC50
values of the molecule indicating that GUNW-3 is not cytotoxic. For brain targeting, our
data with ex-vivo imaging of the brains shows that the brain uptake of DiR, a dye,
delivered by GUNW-3 micelles were 5 times higher than that of the control liposome and
12 times higher than that of free DiR at the first hour. After 48 h, the brain uptake of DiR
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delivered by GUNW-3 micelles was 6.5 times higher than that of the control liposome
and 14 times higher than that of free DiR.
GUNW-3 was also found to help deliver liposomes to the brain most likely by
embedding the hydrophobic cholesterol part into the liposome double lipid layer and the
hydrophilic GSH part floating on the surface of the liposomes for brain targeting. Our
data from ex-vivo imaging of the brains demonstrate that GUNW-3 liposomes were able
to significantly (>3 folds) improve the delivery of DiR to the brain and retain in the brain
well when compared with the control liposomes.
Liposomes and micelles are known effective drug carriers that can be used to
deliver various drugs or compounds such as small molecule therapeutics, DNA, RNA,
and proteins (e.g., antibodies). Liposomes and micelles can encapsulate drugs and protect
them from in vivo/in vitro degradation. They can also help reduce drug clearance,
increase in vivo drug half-life, enhance the drug payload, control drug release, and
improve drug solubility. The abilities to deliver DiR to the brain by GUNW-3 micelles
and GUNW-3 liposomes warrantee further investigation of these two brain targeting
delivery systems for delivering compounds to the brain for brain disease treatment or
prevention.
In summary, we have synthesized and characterized the rationally designed
GUNW-3 as a brain targeting agent. GUNW-3 micelles and GUNW-3 liposomes showed
promising brain targeting abilities. GUNW-3 micelles and GUNW-3 liposomes will be
promising delivery systems for therapeutic and diagnostic molecules.
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Chapter 1.
1.1

Introduction

Brain
The human brain is the most complex organ that is made up by ~100 billion

neurons and consists of three main parts; cerebrum, cerebellum, and medulla (Figure 1.1)
[1-3]. Although the brain weighs only 2% of the body weight, 15% of the blood volume
and 20% of the total oxygen supply are received by the brain [4, 5].Together with the
spinal cord, the brain is known as the central nervous system (CNS). The CNS functions
by receiving and processing signals and sending orders to all human organs to control the
activities of the body [6]. The brain is protected by head bone of skull and presence of the
blood brain barrier (BBB)[7].

2

Figure 1.1 Brain.
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1.2

Blood Brain Barrier

1.2.1

History
The concept of the BBB was first introduced after a series of experiments

conducted by Paul Ehrlich in the late 19th century. By using a water-soluble dye, aniline,
Ehrlich found that the dye stained all the tissues except the brain and spinal cord. The
results of this experiment were the first piece of evidence for the presence of the BBB.
However, Ehrlich incorrectly attributed his finding to the inability of the nervous system
to take up the dye. Edwin Glodmann, Ehrlich’s student, challenged his mentor’s
conclusion by designing an experiment with two parts. First, he used trypan blue injected
intravenously to confirm Ehrlich’s finding that all tissues except the brain and spinal cord
were stained. In his second experiment Glodmann injected trypan blue directly to
cerebrospinal fluid. The injection resulted in staining of the nerve tissues only. This
experiment was the first piece of evidence to indicate the presence of a barrier between
the brain tissue and blood (Figure 1.2). Later, an electron microscopy study in the early
1960’s demonstrated the presence of a tight junction and location of the BBB to the
endothelial cells not to surrounding astrocyte or basement lamina[8, 9].
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Figure 1.2 Illustration for Glodmann’s discovery of the BBB[9].
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1.2.2

Structure of the BBB
The BBB is a selective barrier made by endothelial cells that separates the

peripheral blood circulation form the CNS [7, 10]. The BBB serves as a physical barrier
through the tight junctions of endothelial cells that force molecules to go by transcellular
pathway rather than the paracellular route [10].The junction of endothelial cells was
found to be 50-100 times tighter than that of normal endothelial cells ( Figure 1.3) [11].
Because of this reason, hydrophilic molecules are physically hampered to enter the brain
due to this very tight aqueous space. Overdistribution of different drug efflux pumps such
as P-glycoprotein and multidrug-resistance protein is another feature of the BBB. These
efflux pumps restrict the passage of hydrophobic molecules through the brain cells [7,
12]. Studies reveals that among 6000 drugs in medicinal chemistry database that are used
to treat a small number of selective brain ailments, i.e., insomnia and Alzheimer’s, only
6% of them are brain active due to the presence of the BBB [13]. Interestingly, among all
the drugs only 12% are active in the central nervous system, a scenario that becomes 1%
if affective disorders are excluded [14]. Therefore, enabling a therapeutic to cross the
BBB is a great challenge in the treatment of CNS disorders.

6

Figure 1.3 Basic structure of tight junction of the BBB[8].
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1.2.3

Function of the BBB
Through its unique barrier feature, the BBB helps control and regulate substances

from entry into the CNS to maintain proper functions of the CNS.
A- Ion regulation
The BBB not only provides a stable environment for neural function, but also
keeps the ionic composition optimal for synaptic signaling by a combination of specific
ion channels and transporters. The BBB keeps ions in plasma and CNS as two different
pools and prevents CNS ion pools from the fluctuation of plasma ion pools. Thus the
concentration of potassium in mammalian plasma is approximately 4.5 mM, but in CSF
and brain interstitial fluid (ISF) this is maintained at ∼2.5–2.9 mM, in spite of changes
that can occur in plasma potassium following exercise, a meal, or any other factors [15,
16]. Ca2+, Mg2+ and pH are also actively regulated at the BBB and BCSFB [17, 18]
B- Neurotransmitters
Blood plasma contains high levels of the neuroexcitatory amino acid glutamate
which fluctuate significantly after the ingestion of food. If glutamate is released in an
uncontrolled manner into the brain ISF, as in the case of hypoxic neurons during
ischemic stroke, neural tissues can be damaged considerably and irreversibly. Since the
central and peripheral nervous systems use many of the same neurotransmitters, the BBB
helps separate these two neurotransmitter pools separate to minimize ‘crosstalk’[18, 19].
C- Neurotoxins
The BBB functions as a protective barrier which protects the CNS from
neurotoxic substances in the blood. These neurotoxins can be endogenous metabolites
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and proteins, xenobiotics ingested from the diet or acquired from the environment. A
number of ABC energy-dependent efflux transporters (ATP-binding cassette transporters)
actively pump many of these compounds out of the brain. One of the features related to
the adult CNS is that in adult, neurons are fully differentiated and do not have a
significant regenerative capacity[18]. They are not able to divide and replace themselves
if damaged under normal circumstances, though there is a continuous steady rate of
neuronal cell death from birth throughout life in the healthy human brain with relatively
low levels of neurogenesis [18, 20]. Any acceleration in the natural rate of cell death
resulting from an increased access of neurotoxins into the brain would become
prematurely debilitating.
D- Brain nutrition
The BBB has low passive permeability to many essential water-soluble nutrients
and metabolites required by the CNS. Specific transport systems therefore are expressed
in the BBB to ensure an adequate supply of these nutrients. The differentiation of the
endothelium into a barrier layer begins during embryonic angiogenesis[18].
1.3

Pathways to across the BBB
There are four pathways for compounds to cross the BBB: (i) passive

diffusion which depends on the lipophilicity and concentration gradient of a drug. Passive
diffusion includes paracellular diffusion and transcellular diffusion; (ii) adsorptivemediated endocytosis (AMT) which occurs through nonspecific electrostatic interactions
between the anionic micro domains on the brain capillary endothelial cell membrane and
a cationic drug delivery system such as chitosan, gelatin, or cationic liposomes; (iii)
transporters-mediated transcytosis (TMT); and (iv) receptor-mediated endocytosis
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(RME)[21]. The last two pathways are the basis for a number of endogenous compounds
to cross the BBB despite their unfavorable lipophilicity or molecular sizes for passing
through the BBB (Figure1.4)[10]. Below is a brief description of these four pathways.
A. Paracellular diffusion
Paracellular diffusion occurs between the junction space of two cells. The space is an
aqueous space and allows small water-soluble molecules to pass through. However, the
tight junction of the BBB limits this pathway for aqueous molecules.
B. Transcellular diffusion
Transcellular diffusion is a process where a molecule goes through the cell by passing
through the cell membrane. Since the cell membrane is lipophilic, this pathway requires a
molecule to be lipophilic. This pathway is limited by the presence of drug efflux pumps
in the BBB. Lipophilic or hydrophobic molecules are usually a good substrate for Pglycoprotein (PGP) or multidrug drug resistance proteins (MDR). As a result, a
hydrophobic drug may pass through the BBB but could be pumped back to the
bloodstream resulting in no net distribution to the brain.
C. Receptor-mediated endocytosis
Large endogenous molecules that are needed for brain activities, such as proteins like
insulin (5808 Da) and transferrin (MW=80kDa), are transported by their corresponding
receptors. The protein binds to its receptor and enters the brain through endocytosis.
D. Transporter-mediated transcytosis
Small endogenous molecules such as glucose, amino acids, and short peptides such as
glutathione are transported through their corresponding transporters in the BBB. These
endogenous molecules bind to their corresponding receptors before being transported into
the brain.
E. Adsorptive-mediated endocytosis
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Since the cell membrane is negatively charged, cationic molecules can enter the brain
through nonspecific electrostatic interactions with the anionic micro domains on the brain
capillary endothelial cell membrane. Cationic liposomes enter the brain through this
mechanism. Cationic liposomes are used in this dissertation as one of the controls for
brain targeting.

Figure 1.4 Pathways to across BBB[10].
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1.4

Strategies to overcome the BBB
To overcome the BBB, three strategies has been developed. These three strategies

are invasive approach, chemical property-based approach, and physiological-based
approach.
A-Invasive approach
Invasive approach includes trans-cranial brain drug delivery and reversible BBB
disruption.
i). Trans-cranial brain drug delivery
Trans-cranial brain drug delivery approaches bypass the BBB through
intracerebral implantation, intracerebroventricular (ICV) infusion, or convection
enhanced diffusion (CED).
The factor that limits the intracerebral implantation and ICV infusion is that both
methods rely on drug diffusion to penetrate into the brain from the depot site. Solute
diffusion decreases with the square of the diffusion distance. The concentration of drug
decreases logarithmically with each millimeter of brain tissue that was removed from the
injection site (in the case of intracerebral implantation) or from the ependymal surface of
the brain (in the case of ICV infusion[22]. The concentration of a small molecule was
decreased by 90% at a distance of only 0.5 mm from the intracerebral implantation site in
rat brain [23, 24].
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Figure 1.5 Trans-cranial brain drug delivery[24]
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ii). Reversible BBB disruption
A significant effort was made in delivering drugs to the brain through
BBB disruption after the intracarotid arterial infusion of vasoactive agents such as
those listed in Table 1.1 The intracarotid arterial infusion of 2 M concentrations of
poorly diffusible solutes such as mannitol causes disruption of the BBB owing to
osmotic shrinkage of the endothelial cells. This approach is associated with severe
vasculopathy[25] and chronic neuropathologic changes in rodent models and is
also associated with seizures in either humans or animal models. Plasma proteins
such as albumin are toxic to brain cells,[26] and BBB disruption allows for the
uptake of plasma into the brain[24].
Table 1.1 BBB disruption after the intracarotid arterial infusion[24]

Method

Comment

Hyperosmolar

Leads to chronic neuropathologic changes
and vasculopathy in the brain and seizures

Vasoactive agents

Examples are bradykinin, histamine, and
multiple other vasoactive compounds;
opens BBB in brain tumor to greater
extent than normal brain

Solvents

BBB is solubilized with high dose
ethanol, DMSO, SDS, Tween 80
(polysorbate-80)
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Alkylating agents

Examples are etoposide and melphalan;
may alkylate key sulfhydryl residues
similar to mercury

Immune adjuvants

Freunds adjuvant opens BBB to IgG for
weeks; enable IgG uptake into brain in
rodent vaccine models, such as
Alzheimer’s disease

Ultrasound

The combination of administration of
high-dose air bubbles (2–4 m) and highdose ultrasound (10–1000 watt/cm2) can
induce BBB disruption

Cytokines

Intracerebral interleukin-1 or CXC
chemokines can attract white cells from
blood and cause BBB disruption

Miscellaneous

Intracarotid acid pH, cold temperatures, or
high-dose free fatty acid all cause BBB
disruption
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B-Chemical property-based strategy
Chemical property-based strategy mainly involves small molecules and prodrugs
i) Small molecules
Small molecule drugs can pass the BBB if it is lipid soluble, not avidly bound by
plasma proteins, not a substrate for an active efflux transport system at the BBB, and has
a molecular mass less than 400 Da [24]. The BBB permeation of a drug does not
increase in proportion to drug’s lipid solubility when the molecular weight of the drug is
increased. BBB permeation drops 100-fold as the surface area of the drug increases from
52 Angstroms [27] (e.g., a drug with molecular mass of 200 Da) to 105 Angstroms [27]
(e.g., a drug of 450 Da) [24, 28]. Drug diffusion through a biological membrane is not
analogous to drug diffusion through water. In contrast to water, diffusion of a drug
through a biological membrane depends on the volume of the drug. The classical Overton
rules that relate membrane permeation to solute lipid solubility predict poorly the
molecular weight threshold effect. As noted by Leib and Stein nearly 20 years ago,9 the
molecular weight threshold effect was best predicted by the “hole-jumping” model of
Trauble,10 which posits that solutes undergo a form of molecular “hitch hiking” in
crossing a biological membrane by moving through small holes in the membrane formed
by kinking of the mobile unsaturated fatty acyl side chains in the phospholipid
bilayer[24].
ii). Prodrug
Poor lipophilicity is often a cause for a hydrophilic molecule not able to cross the
BBB. Prodrug is one of approaches to address this issue. By connecting a hydrophobic
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structure to a hydrophilic drug molecule through an enzyme-cleavable bond to form a
hydrophobic prodrug, it provides a compound that is hydrophobic enough to pass the
BBB. The drug will be regenerated from the prodrug once the enzyme-cleavable bond is
cleaved by the endogenous enzyme. Fatty acid, glyceride, and phospholipid have been
used as a hydrophobic structure to increase hydrophobicity for BBB permeation. These
structures have been linked to a hydrophilic drug molecule through an enzyme cleavable
bond such as an ester or amide bond. Prodrug approaches were investigated for a variety
of drugs that contain a group capable of forming an ester or amide, such as an acidic
group [29]. Problems associated with prodrugs include poor selectivity and poor tissue
retention [30].
C- Physiological-based approach
The BBB exhibits a very high resistance owing to the tight junctions, which
tighten adjacent endothelial cells together. Due to the presence of the tight junctions,
paracellular pathway for solute distribution into brain interstitial fluid from blood cannot
occur. Circulating molecules can only pass brain interstitium via a transcellular route
through the brain capillary endothelial membranes. A blood circulating molecule may
reach the brain by lipid-mediated free diffusion if it is lipid soluble, not avidly bound by
plasma proteins, not a substrate for an active efflux transport system at the BBB and has a
molecular mass less than 400 Da as discussed earlier. Circulating molecules may also
reach the brain via certain endogenous transport systems within the brain capillary
endothelium if they have affinity for the transporter. These endogenous transporters can
be broadly classified into three categories: 1) Carrier-mediated transport (CMT); 2) active
efflux transport (AET); and 3) receptor-mediated transport, or RMT [24].
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i)

CMT systems

CMT systems are for hexoses, monocarboxylic acids such as lactic acid, neutral
amino acids like phenylalanine, basic amino acids like arginine, quaternary ammonium
molecules such as choline, purine nucleosides such as adenosine, and purine bases such
as adenine. CMT systems are all members of the Solute Carrier (SLC) gene family. The
glucose carrier in the BBB is GLUT1 (glucose transporter type 1), which is a member of
the SLC2 family; the monocarboxylic acid transporter in the BBB is MCT1, which is a
member of the SLC16 family; the large neutral amino acid and cationic amino acid
transporters in the BBB are LAT1 and CAT1 respectively, which are members of the
SLC7 family; LAT1 and CAT1 are the light chains of heterodimeric proteins, and the
heavy chain of the dimer is 4F2hc, which is a member of the SLC3 family; the adenosine
transporter in the BBB is CNT2, which is a member of the SLC28 family. Each of the
SLC families represent many common genes of overlapping nucleotide identity and some
of the SLC families are made up of over 100 different genes. BBB adenosine transporter
is sodium dependent on the blood side of the endothelium, [31] which rules out the role
of Equilibrative nucleoside transporters ( ENT) carrier in mediating uptake of circulating
adenosine. In addition, there are many other CMT genes expressed at the BBB, which
enable the transport of water-soluble vitamins, thyroid hormones, and other compounds
through BBB. All of these BBB CMT systems, which can be in the dozens, are potential
portals of entry for drugs to reach the brain. The CMT systems are highly stereospecific
pore-based transporters and have high structural requirements for affinity. Therefore, it is
essential to turn a drug molecule into a structure that is still a substrate of the transporter
in order to achieve the purpose of taking the drug into the brain through the transporter in
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the BBB. Understandably, the drug has to be regenerated from the structure once in the
brain. One such example is dopamine which is used to treat Parkinson’s disease.
Dopamine is a very hydrophilic molecule and not able to pass through the BBB.
Carboxylation of dopamine results in the formation of L-DOPA, and L-DOPA is a
substrate for the BBB LAT1. Once across the BBB, dopamine is regenerated through
decarboxylation by aromatic amino acid decarboxylase [24].
ii)

AET

P-glycoprotein is a drug efflux pump and the prototypic AET system at the BBB.
It contributes to the active efflux of molecules from the brain to blood direction. Pglycoprotein is a product of the ABC-B1 gene and one of many members of the ATP
binding cassette (ABC) gene family of transporters. There are several multidrug
resistance protein (MRP) transporters that belong to the ABC gene family. These drug
efflux pumps contribute to the failure of a large number of drugs to reach the brain. One
strategy to increase these drugs’ ability to reach the brain is to develop “co-drugs” that
inhibit BBB AET systems to allow BBB penetration of these therapeutic drugs. The same
strategy can be also applied to overcome drug efflux caused by organic anion transporter
polypeptide (OATP), or organic anion transporter (OAT) transporters [24].
iii)

RMT

Certain large-molecule peptides or proteins cross the BBB via RMT. There are at
least three different classes of BBB receptor systems. The transferrin receptor (TfR) is a
bidirectional RMT system that leads both the receptor-mediated transcytosis of
holotransferrin from the blood to brain direction, and the reverse transcytosis of apo-
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transferrin from the brain to blood direction. The neonatal Fc receptor (FcRn) is a reverse
RMT system that functions only to mediate the reverse transcytosis of IgG from the brain
to blood direction, not the other way around. The type 1 scavenger receptor (SR-VI) is a
receptor-mediated endocytosis system that is engaged in the uptake of modified lowdensity lipoprotein (LDL) from the blood into the intraendothelial compartment, and this
endocytosis is not followed by exocytosis into brain interstitial fluid [24, 32].
1.5

Transporter dependent brain targeting agents
Most brain targeting agents were developed using an endogenous substrate of a

receptor or transporter that is highly expressed on the surface of the BBB as a braintargeting ligand. These substrates include amino acids, glucose, nucleosides, vitamins,
and GSH for transporter-mediated transport, and transferrin, low density lipoprotein, and
lipoprotein for receptor-mediated transport. These endogenous substrates are presented in
table 1.2 [33]
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Table 1.2 Summary of Receptor-mediated transport (RMT) and Carrier-mediated
transport (CMT) dependent brain targeting [33]
Transport System

Receptor /Transporter

Molecules

Receptor-mediated

Insulin receptor (INSR)

Insulin

transport (RMT)

Transferrin receptor (TFR)

Transferrin

Insulin-like growth factor

Insulin like growth factor 1

receptors (IGF1R &

& 2 (IGF-1 & IGF-2),

IGF2R)

mannose-6-phosphate

Leptin receptor (LEPR)

Leptin

Fc-like growth factor

IgG

receptor(FCGRT)
Scavenger receptor type B1 Modified lipoproteins, like
(SCARB1)

acetylated low-density
lipoprotein (LDL)

Carrier-mediated transport

GLUT1 (Glucose

Glucose, hexose, 2-

(CMT)

transporter 1)

deoxyglucose, fluorodeoxy
glucose (positron emission
tomography [PET]
scanning)

LAT1 (large neutral amino

Large and small neutral

acid transporter 1)

amino acids, L-dopa
(Levodopa), α- methyl-
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dopa (Methyldopa), αmethyl-para-tyrosine or
gabapentin (In
parkinsonism, hypertension
and in delivery of
antiepileptic drugs)
CAT1 (cationic amino acid

Basic amino acids, like

transporter 1)

arginine or lysine

MCT1 (monocarboxylic

Lactate, pyruvate, ketone

acid transporter 1)

bodies and monocarboxylic
acid drugs like probenecid
(In treatment of gout and
urinary incontinence)

CNT2 (concentrative

Purine nucleosides, and

nucleoside transporter 2)

certain pyrimidine
nucleosides as uridine (In
delivery of several
anticancer and antiviral
drugs)

SLCs (choline transporter)

Choline (A cholinergic

(Sodium dependent)

agent used in experimental
techniques, not as a drug)
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In principle, any of these substrates can be used as a brain-targeting ligand for
nanoparticles such as liposomes and micelles through coupling the ligand with the
nanoparticles. An approach using a substrate associated with receptor-mediated
endocytosis for brain targeting is the most studied and the most mature one. In this
section we will discuss the most studied receptor-mediated transport (RMT) and carriermediated transport (CMT) to provide a perspective for our investigation which is related
to CMT. Among the substrates for RMT and CMT, transferrin is the most investigated
substrate accounting for 42% of the total publication followed by glucose which accounts
for 20% [34].
i)

Transferrin (Tf)

Transferrin is transported by a RMT. Transferrin was the first one studied for
brain-targeting and also the most investigated one accounting for 42% of the total
publication. In this first study, the human IgG3 immunoglobulin was used as a model
antibody. It was found that attachment of Tf to the hinge region of IgG3 yielded the
highest brain uptake, 0.3% of the injected dose reached the brain. More recently, the
antiviral drug azidothymidine (AZT) has been delivered using Tf-targeted, PEGylated
albumin nanoparticles (PEG-NP). The percentage of AZT recovered in the rat brain was
21.1% using the Tf-targeted PEG-NP, while non-targeted PEG-NP alone showed a 9.3%
accumulation [35]. However, Tf is likely not an ideal brain delivery ligand since the TfR
is nearly saturated with endogenous Tf that are present in the bloodstream at a
concentration of 25 mM, meaning that a Tf-targeted drug would have to compete with a
high concentration of the natural ligand [36]. As an alternative, antibodies against the
TfR have been employed as a ligand for brain targeting. The mouse monoclonal antibody
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(MAb) against the rat TfR, OX26, has been the most thoroughly studied one. Brainderived neurotrophic factor BDNF was coupled to biotin (B) via PEG-hydrazide and
streptavidin (SA) was coupled to OX26. OX26–BDNF was formed as a result of
streptavidin/biotin (SA/B) interactions. BDNF or the OX26–BDNF conjugate were
intravenously administered. It was found that rats given the OX26–BDNF conjugate had
a 243% increase in motor performance when compared to BDNF alone [36]. Tf was also
used to help target other nanoparticles to the brain. Liposomes coated with Tf showed
around 2-5 fold increase in brain targeting compared with liposomes without Tf [37, 38].
Although the TfR has been extensively studied as an RMT system that facilitates
noninvasive delivery of various therapeutics to the brain, drawbacks for the system do
exist. The major drawback is the widespread expression of the TfR on peripheral organs
that limits its capability for specific brain delivery. As a result, Friden and co-workers
reported that only 0.44% of the injected dose reaches the rat brain in their investigation of
using anti-TfR antibody (OX26) as a brain targeting ligand [39]. Similar results were
obtained with the 8D3 antibody [40].The widespread expression of the TfR in non-brain
tissues not only reduces the brain-targeting selectivity but also leads drug side effects to
non-brain tissues. An approach to limit the drug side effects in non-brain tissues is to use
a brain-specific promoter to increase TfR expression in the brain [41]. In addition, there
are non-human TfR antibodies that although these particular antibodies do not recognize
the human TfR, antibodies that do recognize the human TfR and transport into the
primate brain [42]. Use of these antibodies can avoid the drug side effects in non-brain
tissues. However, these antibodies could cause an immunogenic effect since they are not
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of human origin. Strategies to overcome this hurdle will be discussed in reference to the
insulin receptor RMT/anti-insulin receptor MAb system in the next section [36].
ii)

Glucose

Glucose accounts for around 20% of total publication in the brain targeting
field[34]. Two different types of glucose transporter are found in the BBB. The most
prevalent one is the sodium-independent bi-directional facilitative transporter from the
solute carrier 2 (SLC2) family of which there are 14 isoforms (GLUTs 1–14). Given the
widespread distribution, GLUT1 has become one of the most extensively studied of all
membrane transport proteins. At the BBB, a high density of GLUT1 is found in both
luminal and abluminal membranes of endothelial cells. GLUT1 is also found in human
erythrocytes. A number of neuroactive drugs have been conjugated with glucose in order
to target GLUT1 for brain targeting. Four derivatives of the chemotherapy drug
chlorambucil were conjugated with D-glucose to achieve brain targeting through GLUT1
[43]. However, the widespread expression of GLUT1 in other tissues especially in
erythrocytes limits the brain selectivity of GLUT1 [44].
1.6

GSH transporter for brain targeting

GSH is an endogenous tripeptide [45]. GSH is the most essential endogenous
antioxidant that removes reactive oxygen species (ROS) and reactive nitrogen species
(RNS). Because the brain consumes about 20% of the total body oxygen and generates a
large quantity of ROS, GSH is highly needed in the brain. GSH is a water-soluble and
cell membrane impermeable molecule. To enter the brain, GSH has to be transported by a
GSH transporter. The GSH Transporter is a Na+-dependent transporter and localized on
the luminal membrane of endothelial cells [46-49]. To accommodate the brain’s need of
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GSH, GSH transporters are highly expressed on the BBB surface [49-52]. Recently, GSH
transporters have been found effective in facilitating crossing of compounds through the
BBB to reach the CNS. To achieve GSH transporter-mediated BBB crossing, GSH has
been linked to a therapeutic agent (GSH-Drug) to form a prodrug [53]. The prodrug
crosses the BBB by binding the GSH part to a GSH transporter followed by
internalization of the prodrug. GSH has also been used to coat the surface of
nanoparticles such as PEGylated liposomes for brain targeting. GSH coated PEGylated
liposomes encapsulated with doxorubicin showed better permeation in an in vitro BBB
model compared with free doxorubicin [54]. Moreover, G-technology utilized GSHPEGylated liposomes to provide a 3-fold increase in the delivery of a drug to the brain
and the GSH-PEGylated liposomes have undergone clinical trials for brain-targeting [55].
More recently, GSH-conjugated magnetic nanoparticles served effectively as a BBB
shuttle for MRI-monitored brain delivery of paclitaxel in vivo [56].
The aim of this dissertation was to develop a GSH transporter-based brain
targeting agent. GUNW-3 was designed as a GSH transporter-based brain targeting
agent. GUNW-3 is a molecule formed by connecting a hydrophilic GSH molecule to a
hydrophobic cholesterol molecule through a two ethylene glycol unit linker with a hope
that the GSH part can serve as a brain-targeting structure through binding to the GSH
transporter and facilitate the entry into the brain. This dissertation describes the design,
synthesis, and fully characterization of GUNW-3 (Chapter 2). The dissertation also
describes the ability of GUNW-3 to form micelles (GUNW-3 micelles), the ability of
GUNW-3 micelles to cross the BBB to reach the brain, and the ability of GUNW-3
micelles to carry a dye (DiR) to the brain (Chapter 3). Further, the dissertation shows the
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ability of GUNW-3 helps guide liposomes to the brain by forming GUNW-3 liposomes
and the ability of GUNW-3 liposomes to deliver a dye (DiR) to the brain (Chapter 4).
In summary, we have demonstrated a proof of concept that GUNW-3 is an effective brain
targeting agent. It can form brain targeting micelles (GUNW-3 micelles) by itself and
help deliver DiR to the brain. It can also help deliver liposomes (GUNW-3 liposomes) to
the brain and GUNW-3 liposomes were able to deliver DiR effectively to the brain. This
dissertation shows a great potential of GUNW-3 micelles and GUNW-3 liposomes in
delivering a drug to the brain and provides the foundation to pursue further investigation
of GUNW-3 micelles and GUNW-3 liposomes as brain targeting drug delivery systems.
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Chapter 2
2.1

Design, Synthesis, and Characterization of GUNW-3

Introduction
GSH is the major antioxidant compound in the body formed by three amino acid

peptides. Its roles are associated with removal of toxic compounds and involved in other
cellular functions. GSH is transported to the brain through a Na-dependent GSH
transporter. GSH transporters are found to be effective in facilitating crossing of
compounds through the BBB to reach the brain. This chapter presents the rational design
of GUNW-3 as a GSH-transporter mediated brain targeting agent, its synthesis, and full
characterization of the chemical structure of GUNW-3.
2.2

Design of GUNW-3 as a brain-targeting agent
GUNW-3 was designed as a GSH-transporter dependent brain targeting agent.

GUNW-3 is a molecule formed by connecting a hydrophilic GSH molecule to a
hydrophobic cholesterol molecule through a two-ethylene glycol unit linker (Figure 2.1).
The GSH part serves as a brain-targeting structure through binding to the GSH
transporter and facilitates the entry of GUNW-3 into the brain. GUNW-3 was expected to
help deliver compounds to the brain through three different ways. First, the molecule is
expected to be amphiphilic due to the presence of a hydrophobic cholesterol on one end
of the molecule and a hydrophilic glutathione on the other end of the molecule. The
molecule is expected to form micelles (GUNW-3 micelles) with the hydrophilic GSH on
the surface of the micelles and the hydrophobic cholesterol inside to form hydrophobic
core. Micelles can be used to deliver hydrophobic drugs. With the GSH part being on the
surface, GUNW-3 micelles are expected to be brain-targeting micelles, via the GSH
transporter, to help deliver hydrophobic drugs to the brain. It has been reported that the
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more GSH coated on the surface of nanoparticles, the better brain-targeting [33]. Second,
since cholesterol is part of liposomes, GUNW-3 is expected to be used to prepare
liposomes (GUNW-3 liposomes) with the hydrophilic GSH floating on the surface of the
liposomes for brain-targeting and hydrophobic cholesterol being imbedded into the
hydrophobic double lipid layer of liposomes (Figure 2.2). Liposomes are well established
drug delivery systems for both hydrophobic and hydrophilic molecules. The third use of
GUNW-3 is to help deliver an individual drug to the brain by linking the molecule to the
individual drug. In this dissertation, the focus will be on the investigation of the brain
targeting abilities of GUNW-3 micelles and GUNW-3 liposomes.
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Figure 2.1 Schematic drawing of chemical structure GUNW-3 and its formation of
GUNW-3 micelles.
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Figure 2.2 Schematic drawing illustrating GUNW-3 as a part of the components of
liposomes.
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2.3

Experimental Section

2.3.1

Material and instruments
Unless otherwise stated, all chemical reagents and solvents were obtained from

commercial sources and used without further purification. Cholesterol, triethylamine,
pyridine, ethylene glycol, acryloyl chloride, glutathione, Dulbecco’s phosphate buffer
saline (Gicob™DPBS, no calcium, no magnesium,1x) were purchased from Fisher
Scientific (Waltham, MA, USA) and sodium carbonate was purchased from SigmaAldrich (St. Louis, MO, USA).
Flash column chromatography was carried out on a W-Prep 2 XY Yamazen Dual
channel flush chromatography system (San Bruno, California). 1H NMR spectra were
recorded on a Bruker Varian 600 or 400 MHZ spectrometer in deuterated solvents as
indicated. All peaks were given as chemical shift in part per million relatives to TMS
(tetramethyl saline) or DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid) as an internal
standard. Multiplicities are indicted by s (singlet), d (doublets), t (triplet), q (quartet), m
(multiplet), and brs (broad singlet). J value are given in Hz. The high-resolution mass
spectra (HRMS) were obtained on a Bruker Daltonics solariX 12 tesla Fourier Transform
Ion Cyclotron Resonance mass spectrometer (Department of chemistry, University at
Buffalo, NY), and the low-resolution mass spectra were acquired on a Thermoquest
Finnigan LCQ Deca mass spectrometer (Waltham, MA, USA). FTIR spectra were
obtained on a NICOLET 380 FT-IR spectrometer (Thermo Fisher Scientific, Madison,
WI). Melting point were obtained on a MEL-TEMP® melting apparatus (Electrothermal,
Dubuque, IA).
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HPLC/MS analysis was achieved on an Agilent 1260 infinity II HPLC coupled to
Agilent infinity LC/MS. Chromatographic separations were achieved by using Luna 3u
C8(2) column (100×4.6 mm i.d., Phenomenex, Torrance, CA). The mobile phase is
consisted of phase A (ammonium water (pH 10.6)) and phase B (acetonitrile) with a flow
rate of 1 mL/min. Phase B was initially set at 0% for 5 min, increased linearly to 90% over
20 min and held for 3 min, then returned to the initial conditions over 5 min. The system
was re-equilibrated for 3 min before the next injection. The autosampler was thermostated
at 4 °C and a volume of 50 μL was injected with a run time of 33 min. The HPLC was
monitored at 210 nm.
2.3.2

Synthesis of GUNW-3

i.

Synthesis of Cholesterol p-Touenesulfonate (Scheme 2.1, compounds 1)
A solution of cholesterol (5 g, 13.13 mmol), p-toluenesulfonylchloride (3.75 g,

19.7 mmol), triethylamine (2.98 ml), and pyridine (1.5 ml) in anhydrous dichloromethane
(20 ml) was stirred for 24 h at room temperature. The solvents were removed by a rotary
evaporator under a reduce pressure. The residue was purified using a silica gel column
(mesh 200-400) with hexane/ethyl acetate to yield compound 1 as a white powder in 95%
yield. The compound was characterized by 1H NMR (600 MHz, CDCl3) δ 7.72 (d, J = 8.3
Hz, 2H), 7.25 (d, J = 8.0 Hz, 2H), 5.25 – 5.20 (d, 1H), 4.24 (tt, J = 11.4, 4.6 Hz, 1H),
2.36 (4H), 2.22 – 2.15 (m, 1H), 1.90 – 0.74 (m, 38H), 0.58 (s, 3H).
ii.

Synthesis of Cholesterol-ethylene Glycol (Scheme 2.1, compound 2)
To a stirred solution of ethylene glycol (11.77 g,110.9 mmol) in 30 ml dioxane

was added dropwise compound 1 (3 g, 5.5 mmol) in dioxane (5 mL). The mixture was
kept at 70 ˚C for 48 h before removing the solvents using a rotary evaporator under a
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reduce pressure. The resulting residue was purified using a silica gel column (silica size
200-400 mesh) with hexane/ethyl acetate to yield a slightly yellow viscous product in
79% yield. The product was characterized by 1H NMR (400 MHz, CDCl3) δ 5.35 (d 1H),
3.68 (ddd, J = 15.1, 8.6, 4.1 Hz, 8H), 3.26 – 3.12 (m, 1H), 2.38 (d, J = 12.8 Hz, 1H), 2.22
(t, J = 12.0 Hz, 1H), 2.10 – 1.71 (m, 5H), 1.64 – 0.82 (m, 33H), 0.65 (s, 3H).
iii.

Synthesis of Cholesterol-ethylene glycol-acrylate (Scheme 2.1, compound 3)
A solution of acryloyl chloride (0.524 g,6.49 mmol) in anhydrous

dichloromethane (2 ml) was added dropwise to a stirred solution of compound 2 (2.05 g,
4.33 mmol) in anhydrous dichloromethane (15 ml) under argon in an ice bath. The
mixture was stirred for 30 min before removal of dichloromethane under a reduced
pressure by a rotary evaporator. The residue was purified by a silica gel column (silica
size, mesh 200-400) using hexane/ethyl acetate to yield colorless viscous product in 69%
yield. The product was characterized by 1H NMR (600 MHz, CDCl3) δ 6.43 (dd, J =
17.3, 1.4 Hz, 1H), 6.19 – 6.13 (m, 1H), 5.83 (dd, J = 10.4, 1.4 Hz, 1H), 5.43 – 5.24 (m,
1H), 4.48 – 4.22 (m, 2H), 3.79 – 3.73 (m, 2H), 3.67 – 3.61 (m, 4H), 3.31 – 3.07 (m, 1H),
2.37 – 2.30 (m, 1H), 2.21 (m, 1H), 2.03 – 1.78 (m, 5H), 1.61 – 0.84 (m, 33H), 0.67 (s,
3H).
iv.

Synthesis of GUNW-3
Glutathione (0.911 g, 2.96 mmol) and sodium carbonate (0.314 g, 2.96 mmol)

were dissolved in water (6 mL) before added to a stirred solution of compound 3 (1.5 g,
2.96 mmol) in tetrahydrofuran (7 mL). Th mixture was stirred overnight at room
temperature followed by addition of water (50 mL). The solution was frozen and
lyophilized to yield the crude GUNW-3. GUNW-3 was purified through precipitation
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using water (pH4)/acetonitrile (1:1 ratio) and separated by filtration to yield white
powder in 40% yield. The product was characterized by 1H NMR, and HRMS. The purity
of the compound was determined by HPLC to be 97%. The melting point of the
compound was determined to be 200 ˚C by a MEL-TEMP® melting apparatus. 1H NMR
(600 MHz, D2O) δ 5.34 (s, 1H), 4.28 (s, 1H), 3.72 (dd, J = 97.5, 31.9 Hz, 11H), 3.23 (d, J
= 72.2 Hz, 2H), 3.00 (s, 1H), 2.87 (s, 4H), 2.44 (d, J = 82.1 Hz, 2H), 2.18 (d, J = 23.9 Hz,
3H), 1.91 (s, 3H), 1.82 – 0.10 (m, 39H). HRMS calculated for C44H73N3O10S (M+Na) +
(m/z) 858.4914, found 858.4909.
2.3.3

Purification and chemical stability of GUNW-3
Stock solutions of GUNW-3 were prepared by dissolving GUNW-3 in a solution

of methanol and ammonium water (1:1 ratio, pH 10.8) to obtain the concentration of 1
mg/ml. Calibration curves were constructed in a solution of methanol and ammonium water
(1:1 ratio, pH 10.8) by preparing a series of concentrations of GUNW-3 (62.5, 125, 250,
500, 750 and 1000 μg/ml).
FTIR analysis of GSH and GUNW-3 were conducted on a NICOLET 380 FTIR
spectrometer and the OMIC was used for data analysis.
LC/MS analysis of GUNW-3 was conducted on a (xxx Instrument name). SIM
was used for MS analyses and performed in both negative-ion mode (SIM: 834.6) and
positive mode (SIM:837.4). The capillary temperature was set at 4000V and the fragmentor
of the compound was set at 135V. The temperature of the ESI source during the run was
set at 350 °C for the desolvation gas. The gas flow was set at 11L/h.
GUNW-3 mass spectrum was obtained by direct infusion into Finnegan TSQ
quantum.
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2.3.4

In-vitro toxicity study
An African green monkey kidney fibroblast cell line (CV-1) from American Type

Culture Collection (ATCC) and a human lung squamous carcinoma cell line (NCI-H226)
from the National Cancer Institute were used for the cytotoxicity studies. Cells were
grown seeded on a 96-well plate at a concentration of 3000 cells/well. RPMI 1640
growth medium supplemented used with 10% FBS, 100 unit/ml of penicillin (Mediatech,
Inc, Herndon, VA) in humidified atmosphere containing 5% CO2 at 37˚C. After 24hrs,
cells were treated with different concentrations of GUNW-3. The MTT assay was used to
determine the cell viability after a 4-day treatment.
2.3.5

In-vivo toxicity study
GUNW-3 (26 mg/ml, injection volume) was intravenously injected to female

C57BL/6 mice (6-8 weeks old, 17 g from Jackson Laboratory (Bar Harbor, ME, USA))
for 4 days. The mice were monitored for any sign of toxicity (food intake, weight,
abnormal activities and etc) for 4 days. Mice were sacrificed on day 5 and submitted to
the Animal Disease Research & Diagnostic Laboratory at South Dakota State University
for a pathological examination by a university veterinarian.

2.4

Result and Discussion

2.4.1

Synthesis of GUNW-3
GUNW-3 was synthesized in a total of 4 steps. The first step was tosylation of

the commercially available cholesterol with 4-methylbenzene-1-sulfonyl chloride
(Scheme 2.1, step a) in the presences of pyridine and triethylamine to produce tosylated
cholesterol (1) in 95% yield (Scheme 2.1). Compound 1 was added with ethylene glycol
(2,2'-oxydiethanol) in Dioxin (Scheme 2.1, step b) to produce cholesterol-ethylene glycol
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(2) in 79 % yield. Cholesterol-ethylene glycol (2) reacted with acryloyl chloride (Scheme
2.1, step c) in the presence of triethylamine to form cholesterol-ethyleneglycol-acrylate
(3) in 69% yield. Michael addition coupling of GSH to compound 3 was achieved in the
presence of sodium carbonate to complete the synthesis of GUNW-3 in 40% yield
(Figure 2.3). The reaction conditions for the synthesis were not optimized. GUNW-3 was
characterized by 1H NMR and HRMS. The purity of GUNW-3 was confirmed to be 97%
by HPLC.
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Figure 2.3 Synthetic schemes of GUNW-3.
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2.4.2

Purity and stability of GUNW-3
The purity of GUNW-3 was checked by HPLC and determined to be 97% as shown

by a representative HPLC chromatogram (top one in Figure 2.3). For a comparison, a
representative HPLC chromatogram derived from solvent only was also given (bottom one
in Figure 2.4). As one can see that GUNW-3 (the peak at 21 min in the top chromatogram)
was the only peak observed besides the solvent peaks.

.

Figure 2.4 Representative HPLC chromatogram of GUNW-3 at concentration of 1

mg/ml and the blank solvent.
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The stability of GUNW-3 in a solution of methanol-ammonium water (1:1 ratio,
pH 10.8) was checked continuously for 7 days (Figure 2.3). As shown in the figure,
GUNW-3 was stable in the first 3 days. However, it started to decompose quickly after 3
days. The accelerated decomposition after day 3 suggests a possibility of decomposition
product-facilitated decomposition (Figure 2.5).
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Figure 2.5 Stability of GUNW-3 in a solution of methanol-ammonium water (1:1 ratio,
pH:10.8, ±SD, n=3).
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2.4.3 Confirmation of S-link isomer vs N-link isomer
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Figure 2.6 Chemical structures of GUNW-3 and its N-link isomer
The Michael addition coupling of GSH to compound 3 (Scheme 2.1) may
proceed with two possibilities: addition of the SH group to yield GUNW-3 (S-link
isomer) and addition of the basic amino group of the glutamate residue to produce
GUNW-3’s N-link isomer (Figure 2.6), although addition of the GSH group is expected
to be the dominating reaction. To confirm GUNW-3 is the product, two analytical
methods were employed: FTIR and MS. In FTIR, the -SH group has a distinct peak at
2516.7 cm-1 as observed in the FTIR spectrum of GSH (Figure 2.7A). The peak at 2516.7
cm-1 disappeared in the product obtained from the Michael addition reaction (Figure
2.7B) confirming that the -SH is no longer present in the obtained product which suggests
that the reaction occurred through the addition of the -SH group to compound 3 and the
product is GUNW-3 (the S-link isomer).
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A

B

Figure 2.7 FITR spectra of GSH (A) and GUNW-3 (B)
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The confirmation of the obtained product was GUNW-3 was further achieved by
LC/MS/MS. Based on the structures of the S-link isomer and N-link isomer, the
fragmentation of these two isomers are expected to be different. For the S-link isomer,
two neutral losses are expected: a neutral loss of glycine (C2H5NO2, 75Da) and a neutral
loss of pyroglutamate (C5H7NO3, 129Da). These two neutral losses were observed in the
MS/MS spectrum: m/z fragment at 762.45 for the neutral loss of glycine and m/z
fragment at 708.29 for the neutral loss of pyroglutamate (Figure 2.7). It needs to be noted
that these expected two neutral losses were also reported in the literature for the S-link
isomer (Yue’s reference). The m/z fragments at 468.70 and 369.82 in the mass spectrum
of GUNW-3 (Figure 2.8) were the fragment generated from a neutral loss of cholesterol
and cholesterol ion respectively. Therefore, the mass spectrum matches well with the
structure of the S-link isomer (GUNW-3) not the N-link isomer. If it would be the N-link
isomer, a neutral loss of 178.0412Da (C5H10N2O3S) would have been observed as
reported in the literature for the N-link isomer [57].
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Figure 2.8 Mass spectrum of GUNW-3 obtained from LC/MS/MS on a positive mode.
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2.4.4

Cell viability test of GUNW-3
The cell viability test of GUNW-3 was conducted with two cell lines: one normal

cell line (CV-1 cells) and one cancer cell line (NCI-H226 cells). A dose-response curve
revealed IC50 values of 0.65 mM and 0.47 mM for NCI-H226 cells and CV-1 cells
respectively which are much higher than the critical micellar concentration (CMC) (3.9
μM) of GUNW-3 (in Chapter 3) and much higher than the concentration of GUNW-3
used in brain targeting micelles (GUNW-3 micelles) or liposomes (GUNW-3 liposomes).
Figure 2.9 presents representative dose-response curves for the determination of the IC50
values.
A

B

Figure 2.9 Dose-response curves for the determination of IC50 values of GUNW-3 with
NCI-H226 cell line (A) and CV-1 cell line (B) (mean ±SD, n=3).
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2.4.5

In-vivo toxicity
A preliminary in vivo toxicity study was conducted with one mouse. For this work

we used a dosage that is 3.7 time higher than the dose used for GUNW-3 micelles
(Chapter 3) and GUNW-3 liposomes (Chapter 4) and the dose was used daily for four
days instead of a single dose in the in vivo brain-targeting studies (Chapters 3 and 4).
Mice were closely monitored daily. No abnormal activities (loss of food intake, weight
loss, and behavior abnormality) were observed during the 4 days. Mice were sacrificed
on day 5 and subjected for a pathological examination in the Animal Disease Research &
Diagnostic Laboratory at South Dakota State University by a university pathologist. No
significant gross and microscopic lesion were noted for all organs examined (Figure
2.10).
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Figure 2.10 The report from the Animal Disease Research & Diagnostic Laboratory for a
pathological examination of mice treated with GUNW-3 micelles or GUNW-3 liposomes
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In summary, GUNW-3 was designed as a brain targeting agent. The compound
was successfully synthesized in a total of 4 steps. In this chapter we confirmed the
chemical structure of GUNW-3. We also confirmed that GUNW-3 is relatively stable. A
cell viability study showed the IC50 values of GUNW-3 in the NCI-H226 cell line and
CV-1 cell line were to be 0.65 mM and 0.47 mM respectively. A preliminary in vivo
toxicity study of GUNW-3 showed that no organ toxicity was observed as reported by
the pathologist at a dosage that was 3.7 times higher than the dose used and four time
more frequent than that used for brain targeting of GUNW-3 micelles and GUNW-3
liposomes.

48
Chapter 3
3.1.

Introduction

3.1.1

Micelles

Brain Targeting of GUNW-3 Micelles

Amphiphilic molecules are the molecules that have a hydrophilic group and a
hydrophobic group. Amphiphilic molecules can undergo self-assembly to form micelles
when they dissolve in a solvent [58]. Micelles are an aggregation form of the molecule in
solution. In an aqueous solution, amphiphilic compounds arrange themselves in a way
that the hydrophobic groups will make a core while the hydrophilic groups will be
oriented toward water. This type of micelles is known as the normal micelles. However,
when present in an organic solvent the arrangement of amphiphilic molecules will be the
opposite which is known as reverse micelles.
Micelles are nanoparticles with a typical particle size of 20 nm to 200 nm[58].
Micelles can be classified based on its materials, the manner of self-assembly, and the
surface charge. Based on the materials, micelles can be classified as lipid micelles,
polymer micelles, oligopeptide micelles, and polysaccharides micelles. The materials
used to make micelles can be employed to control the particle size, ability of drug
encapsulation, biological stability, and drug releasing rate of micelles. Based on the
manner of self-assembly, micelles can be classified as normal micelles, reverse micelles,
and unimolecular micelles of which one molecule can assemble to form one micelle.
Unimolecular micelles are a polymer that has multiple hydrophilic and hydrophobic
groups. The surface charge of micelles can lead to three types of micelles: nonionic
(neutral), cationic (positive), and anionic (negative) micelles.
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Critical micelles concentration (CMC) [59] is a critical parameter for micelles.
CMC is a concentration that an amphiphilic molecule starts to form micelles. At
concentration lower than the CMC, the molecule will exist as a monomer not micelles.
3.1.2

Micelles in drug delivery
Micelles are considered as an effective drug delivery system. Regular micelles are

the most commonly used micelles and used to deliver poorly water-soluble drugs which
can be encapsulated in the hydrophobic core of micelles. On the other hand, hydrophilic
drugs can be effectively encapsulated in reverse micelles in the hydrophilic core. Reverse
micelles are usually used in an oily injection. Clinical applications of reverse micelles are
USP steroid injection and some biocompatible oily formulations used for oral delivery
[60]. CMC is one of the critical parameters to be used to determine if the micelles can be
used for a clinical application. Micelles with low CMC (in μM) are required for a clinical
application since micelles with high CMC will dissociate to become a monomer upon
dilution in bloodstream. Only a few micelle formulations, manly polymeric micelles,
have made it to clinical studies (Table 3.1) [58, 61].
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Table 3.1 Micelles formulations in clinical trials
Name

Clinical phase

Condition

Completed

NCT#

date
Paclitaxel

Phase IV

polymeric

Recurrent

Unknown

00912639

2013

00876486

2013

00886717

Ongoing

03585673

breast cancer

micelles
Genexol-PM

Phase III

Taxanepre
treated
recurrent breast
cancer

Paclitaxel

Phase II

polymeric

Advanced
ovarian cancer

micelles
Docetaxel-PM

Phase II

Esophagus
Squamous cell
carcinoma

3.1.3

Micelles for Brain Targeting

3.1.3a Ligand-Micelle-Based Active Brain Targeting
Ligand-mediated delivery of bio-actives using micelles can enhance the efficacy
of bio-actives. For example, MPEGPCL-Tat (methoxy poly(ethylene glycol)/poly(ε-
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caprolactone)) polymer micelles modified with human immunodeficiency virus Tat
protein as the brain-targeting agent and coumarin as a model drug showed higher brain
distribution of coumarin [62]. Polymeric micelles modified with p-hydroxybenzoic acid
(p-HA) as the brain-targeting agent was found effective in improving cellular uptake of
docetaxel in brain capillary endothelial cells (BCECs) by 1.2 times over the unmodified
micelles, 1.2 times more cytotoxic than unmodified micelles, and 1.7 times more
effective than free drug. Ex vivo near infrared fluorescence imaging showed 1.3-1.8
times higher brain uptake than unmodified micelles [63]. Similarly, cyRGD-installed
polymeric micelles were constructed and chemically conjugated with epirubucin via a
pH-sensitive hydrazone bond for the effective brain delivery in glioblastoma (GBM). The
micelles easily penetrated the U87MG cell-derived spheroid model and in vivo studies
clearly showed that accumulation of the drug was four folds higher than the non-CyRGD
tagged micelles [64, 65]

3.1.3.b Passive Targeting
Passive targeting of micelles crosses the BBB mostly through adsorptivemediated endocytosis mechanism. A number of these micelles have been developed and
found effective in brain targeting. Novel polyion complex micelles composed of methoxy
poly(ethylene glycol)-grafted chitosan and encapsulated with all-trans retinoic acid
(ATRA) were developed for brain tumor treatment. In vivo imaging of polymeric
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micelles (CS-SA) of stearic acid (SA)-modified chitosan (CS) loaded with doxorubicin
revealed that CS-SA micelles were capable of crossing the BBB and delivered the drug
effectively into the brain. Polymeric micelles NK012 loaded with an anticancer agent
SN-38 was found effective against xenografted rat glioblastoma with less toxicity.
Polymeric micelles constructed with novel cross-linked hyaluronan styrylpyridinium
(HA-SbQ) copolymer and loaded with PTX were found to give higher cellular uptake by
bone marrow-derived macrophages (BMM) and U87 cells. Cytotoxic studies revealed
that the formulation was more potent than the naı¨ve drug. Cholesterol-conjugated
polyoxyethylene sorbitol oleate (CPSO) amphiphilic copolymer was used to prepare selfassembled CPSO micelles for PTX delivery in glioblastomas. The researcher claimed,
after in vitro studies in U87 cells and in vivo studies, that the CPSO micelles were more
biocompatible, safe, and better capable of delivering the drug across the BBB than Taxol
along [65].

3.1.4

GUNW-3 micelles
GUNW-3 is a molecule with cholesterol at one end of the molecule and

glutathione at the other end (Figure 3.1). The cholesterol part and glutathione part are
connected by a short ethylene glycol link (figure 3.1). Cholesterol is an endogenous
compound and plays an important role in the cell membrane structure[66]. Structurally,
cholesterol is a very hydrophobic molecule with a molecular weight of 386.6 and log P
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value around 7. On the other side, glutathione is a very hydrophilic endogenous
antioxidant tripeptide with a molecular weight of 307.3 and a log P value of -6.3 [67].
This big difference in the log P values of cholesterol and glutathione, with one being
highly hydrophobic and the other highly hydrophilic, is the basis for GUNW-3 to be
amphiphilic. We have found that GUNW-3 can form micelles by itself with a low CMC.
The ability of GUNW-3 to form micelles is properly due to the amphiphilic structure
feature with a hydrophobic part (cholesterol) at one end of the GUNW-3 molecule and
the hydrophilic part (glutathione) at the other end of the molecule. This part of the project
was aimed to investigate the basic properties of GUNW-3 micelles and the braintargeting ability of GUNW-3 micelles by using DiR, a near infrared (NIR) fluorescent
cyanine dye, as a model compound to track distribution of GUNW-3 micelles and also to
investigate the ability of GUNW-3 micelles to deliver DiR.

Figure 3.1 Chemical Structure of GUNW-3.

54
3.2 Experimental Section
3.2.1

Materials and instruments

Unless otherwise stated, all chemical reagents and solvents were obtained from
commercial sources and used without further purification. GUNW-3 was prepared based
on a procedure in Chapter 2 of this dissertation. DiR [or DilC18(7)], Ethanol,
tetrahydrofuran (THF), cholesterol, Dulbecco’s phosphate buffer saline (Gicob™D PBS,
no calcium, no magnesium,1x) were purchased from Thermo Fisher Scientific (Waltham,
MA, USA). Pyrene and lecithin (phospholipid 90G) were obtained from lipoid
(Ludwigshafen, Germany). Dimethyldioctadecylammonium bromide (DDAB) was
obtained from AppliChem (Darmstadt, Germany). Sephadex column (PD10 column, GE
health care, Little Chalfont, UK), RPMI 1640 growth medium supplement with 10% FBS
100 units/ml of penicillin was obtained from Mediatech, Inc. (Hendon, VA). In-vivo and
ex-vivo imaging was obtained on a Xtreme in-vivo imaging (Bruker).
3.2.2

Procedures

3.2.2.1 The Critical micellar concentration of GUNW-3
The CMC of GUNW-3 was determined by using pyrene as a fluorescent probe.
Briefly, 1 mg/ml of pyrene in acetone (6×10-6 M) was added to a series of vials and
evaporated under nitrogen. Different concertation of GUNW-3 from 0.00001 mg/ml to 1
mg/ml was added to the vials. The mixtures were vortexed for 2 min. The fluorescence
intensity from each vial was determined by a spectrofluorometer using the excitation
wavelength of 334 nm and emission wavelengths of 375 nm for I1 and 384 nm for I3
respectively. The CMC is the concentration at the intersection of the two straight lines of
the I3/I1 ratio low concentration and high concentration[68-70].
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3.2.2.2 Preparation and characterization of GUNW-3 DiR micelles
GUNW-3 Dir micelles were prepared by a film-dispersion method. Briefly, 7 mg
of GUNW-3 and 0.025 mg of DiR were suspended in ethanol (50µl) and vortex-mixed.
The ethanol was evaporated by using nitrogen. The residue was hydrated with
Dulbecco’s phosphate buffer saline (DPBS). The solution was centrifuged at 14000 rpm
for 10 min to remove insoluble DiR to give GUNW-3 DiR micelles [71].
The particle size and zeta potential of GUNW-3 DiR micelles were determined by
using Zetasizer. Briefly, a freshly prepared GUNW-3 DiR micelle solution was diluted
(0.5:100) with deionized water before used for particle size and zeta potential
determination by the dynamic light scattering (DLS) method using Zetasizer (Malvern
instrument, Westborough, MA).

3.2.2.3 Preparation of control DiR liposomes
In addition to free DiR, control DiR liposomes were employed as a control for
GUNW-3 DiR micelles. Control DiR liposomes were prepared by the Thin Layer
Hydration method. Briefly, Lecithin (7 mg/ml), cholesterol (1 mg/ml), DDAB (2 mg/ml),
and DiR (0.025 mg/ml) were dissolved in chloroform. The thin film was formed after
rotavapory evaporation of solvents overnight under a reduced pressure. The thin film was
then hydrated using DPBS solution for 10 min and vortex-mixed for 2 min. Liposome
size reduction was achieved by a bath sonicator for 20 min (4 min sonication with 1 min
break) followed by extrusion through a 200 nm, and then 100 nm filter. Sephadex column
(PD 10 column, GE health care, Little Chalfont, UK) was used to separate untrapped DiR
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by centrifugation at 2500 rpm for 2 min to yield the control DiR liposomes. The particle
size and zeta potential were determined by the Dynamic light scattering (DLS) method
using Zetasizer (Malvern instrument, Westborough, MA) after a dilution (0.5:100) of the
DiR liposomes with deionized water.
3.2.2.4 Determination of DiR encapsulation efficiency and loading capacity
The encapsulation efficiency (EE%) and loading capacity (LC%) of GUNW-3
DiR micelles and control DiR liposomes were determined by fluorescence. The GUNW-3
DiR micelles or the control DiR liposomes were dissolved in DMSO to a concentration of
7 mg/ml. The GUNW-3 micelles solution or control liposomes solution (60 μl) and
DMSO (40 μl) were pipetted into a well of a 96-well plate for fluorescence intensity
measurement on a fluorescent plate reader by using 730 nm and 780 nm as the excitation
and emission wavelengths. A calibration curve was constructed by spiking a known
concentration of DiR to a blank liposomes in DMSO[72].
3.2.2.5 Stabilities of GUNW-3 DiR micelles and control DiR liposomes
A stability study of GUNW-3 DiR micelles was conducted at 4 ˚C to determine
the storage stability of the micelles. Since micelles will encounter proteins once in the
blood circulation, the stability of GUNW-3 in the presence of serum at 37 ˚C was also
checked. The particle size was used as a parameter for micelle stability studies.
3.2.2.5a Stabilities of GUNW-3 DiR micelles and control DiR liposomes
The stability of freshly prepared GUNW-3 DiR micelles or control DiR liposomes
was checked, after a 0.5:100 dilution with deionized water as described earlier, every 24
h at 4 ˚C for 5 days. The particle size was determined by the dynamic light scattering
(DLS) method using Zetasizer (Malvern instrument, Westborough, MA).
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3.2.2.5b Stabilities of GUNW-3 DiR micelles and control DiR liposomes in the
presence of FBS
The stabilities of GUNW-3 DiR micelles and control DiR liposome were checked
in the presence of RPMI 1640 growth medium supplemented with 10% FBS at 37 ˚C.
Samples were diluted with deionized water (0.5:100) before particle size determination
The particle size was checked by the dynamic light scattering (DLS) method using
Zetasizer (Malvern instrument, Westborough, MA).
3.2.2.6 Whole body fluorescence imaging of mice
Females BALB/Cj mice (6-8 weeks old, 17-20 g) were used for this work. Mice
were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and acclimatized to a
laboratory condition for one week before the experiment. For the experiment, mice were
divided into 3 groups and intravenously injected with GUNW-3 DiR micelles, control
DiR liposome, or free DiR (250 µg DiR/Kg) respectively through the tail vein.
Fluorescence images for the whole body were taken at 15 min, 1 h, 24 h, and 48 h post
injection. Images were analyzed using the Bruker MI SE software. All procedures were
approved by the Institutional Animal Care and Use Committee (IACUC) at South Dakota
State University, Brookings, SD, USA.
3.2.2.7 EX-vivo brain and organs imaging
To assess organ distribution, mice were sacrificed 1 h and 48 h after a single dose
tail vein injection. The heart was perfused with DPBS before organs were collected to
remove blood in tissues. Images of organs were obtained using Xtreme in-vivo imaging
(Bruker) and analyzed using the Bruker MI SE software.
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3.2.2.8 Statistics
In this work, results from in vitro experiments were reported as mean ± standard
deviation (SD) of n=3 and results from in vivo experiments were reported as means with
standard error of mean (SEM). Student’s t-test was used to compare two groups and oneway ANOVA with a Tukey post-test was used to compare all three groups. The results
are reported using GraphPad Prism 8 to demonstrate the statistical difference (p ˂ 0.05).
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3.3

Result and Discussion

3.3.1

The critical micellar concentration (CMC) of GUNW-3 micelles
CMC is a critical micelle parameter to reflect the stability of micelles and is also a

parameter to determine if the micelles are stable enough to be used for a clinical
application. The CMC of micelles used for a clinical application needs to be in μM
concentration so that the micelles are stable enough to remain as micelles once being
diluted in the blood stream.
In this study, the CMC of the GUNW-3 micelles was measured using pyrene - a
fluorescens probe. Pyrene is a hydrophobic molecule that has a very low water solubility.
As demonstrated in Figure 3.2, pyrene showed a low but constant fluorescence intensity
before GUNW-3 formed micelles (Figure 3.2). The fluorescence intensity took a turn and
increased dramatically indicating that GUNW-3 started to form micelles – a phenomenon
resulting from the fact that pyrene started to be encapsulated inside the micelles which
increased significantly the solubility of pyrene that in turn significantly increased the
fluorescence intensity. The CMC of GUNW-3 was determined to be 3.3 μg/ml (3.9 μM)
(Figure 3.2). The low μM CMC of GUNW-3 suggests that GUNW-3 micelles are stable
enough to be used for a clinical application.
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Figure 3. 2 A plot of I3/I1 versus concentration of GUNW-3. Pyrene was used as a
fluorescent probe. Data were presented as the mean ± SD (n=3).
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3.3.2

Preparation and characterization of GUNW-3 DiR micelles
Figure 3.3 provides a graphic demonstration for the preparation of GUNW-3 DiR

micelles. GUNW-3 formed micelles through self-assembly once its concentration
exceeded the CMC. The average particle size of GUNW-3 DiR micelles was 29.09 nm ±
5 (Figure 3.4.A) and the size distribution parameter PDI (poly distribution index) was
0.126. The particle size of GUNW-3 micelles was well below 150 nm which is the
maximum particle size for brain targeting. The zeta potential of GUNW-3 micelles was
found to be -19 mV ± 2.1 (Table 3.2).

Figure 3. 3 Preparation of GUNW-3 micelles.
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3.3.3

Preparation and characterization of control DiR liposomes
Control DiR liposomes were prepared based on the thin layer hydration method.

The average size and size distribution of the prepared control DiR liposomes are
illustrated in Figure 3.4. The average size of the control DiR liposomes was 99.56 nm ±
2.5 with a PDI value of 0.205. The zeta potential of the control DiR liposomes was +19.2
mV±6.53 (Figure 3.4.B, Table 3.2). The positive charge on the liposome surface was
from cationic DDAB. Cationic liposomes are known to have better brain targeting when
compared with neutral liposomes and anionic liposomes due to their electrostatic
interaction with the negatively charged cell surface (adsorptive-mediated endocytosis)
[73, 74].
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A

B

Figure 3.4 Particle size and size distribution of GUNW-3 DiR micelles (A) and control
DiR liposomes (B).
Table 3.2 Nanoparticle parameters of GUNW-3 DiR micelles and control DiR liposomes.
Results are presented as mean ±SD (n=3).
Nanoparticles

GUNW-3 DiR
micelles
Control DiR
liposomes

Theoretical
loading
(%)
0.35

Particle PDI
Size
(nm)
29.09 ± 0.126
5

Zeta
(EE%)
potential
(mV)
-19 ±
68±0.6
2.1

0.24 ±
0.0015

0.25

99.5 ±
2.5

+19.2
±6.53

0.17 ±
0.0013

0.205

69 ± 0.7

(LC%)
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3.3.4

Determination of DiR encapsulation
The encapsulation efficiency (EE%) and loading capacity (LC%) of GUNW-3

DiR micelles and control DiR liposomes were determined by fluorescence using 730 nm
and 780 nm as the excitation and emission wavelengths. The EE% and LC% of the
GUNW-3 micelles were found to be 68±0.6 % and 0.24 ± 0.0015% respectively while
the EE% and LC% of the control DiR liposomes were found to be 68±0.7% and 0.17 ±
0.0013% respectively (Table 3.2).
3.3.5

Stabilities of GUNW-3 DiR micelles and control DiR liposomes

3.3.5.1 Stabilities of GUNW-3 DiR micelles and control DiR liposomes
The stabilities of GUNW-3 DiR micelles and control DiR liposomes were studied
at 4 °C for 5 days in the DPBS. The particle size was used as a parameter to reflect the
stability. The data are shown in Figure 3.5.A. The particle size of the control DiR
liposomes on day 1 was 99.56 nm ± 2.89 exhibiting no statistical difference when
compared with 102.83 nm ± 1.2 on day 5. No statistically significant difference was
observed either for the particle size of GUNW-5 micelles on day 1 (29.2 nm ± 5.08) vs
that on day 5 (29.7 nm± 1.2). These results suggest that both GUNW-3 DiR micelles and
control DiR liposomes were stable in the stock solution at 4 °C – a storage temperature
(Figure 3.5.A).
3.5.5.2 Stabilities of GUNW-3 DiR micelles and control DiR liposomes in the
presence of FBS
In order to achieve significant brain uptake, nanoparticles need to have good
stability in the presence of proteins which are present in the blood circulation. To check
the stability in the presence of proteins, GUNW-3 DiR micelles or control DiR liposomes
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were incubated in the RPMI 1640 growth medium supplemented with 10% fetal bovine
serum (FBS) at 37 °C. As shown in figure 3.5.B, the particle size of GUNW-3 DiR
micelles increased from ~27.7 nm to ~105.6 nm then continued to increase to reach 229
nm at 24 h. The particle size of GUNW-3 micelles remained relatively constant (~229
nm) after 24 h until 48 h when the experiment ended demonstrating a two-phase increase
in particle size. The two-phase increase in particle size suggests possibly two different
mechanisms to account for these two phases in particle size increases. One is that
GUNW-3 quickly complexed with FBS that increased the particle size initially (first
phase size increase), then followed by a slow increase in particle size which might be
caused by particle aggregation. Binding of GUNW-3 micelles to FBS appears to be
consistent with a literature report on the binding of GSH to BSA. It was reported that
GSH can bind to BSA at site I in subdomain IIA based on the molecular docking results.
The binding process is dominated by hydrogen bonds and concluded that there is a strong
interaction between GSH and BSA. Therefore, it is quite likely GUNW-3 binds to BSA
in a similar manner [75]. Similar to GUNW-3 DiR micelles, control DiR liposomes
quickly changed the particle size from ~120 nm to ~367.6 nm (Figure 3.5.C). However,
no second phase particle size increase was observed for control DiR liposomes. It is
noted that the required particle size for brain-targeting should be below ~150 nm. Larger
particles will not be able to enter the brain. Therefore, an increase in particle size
observed with GUNW-3 micelles and control DiR liposomes will have impacts on their
abilities to enter the brain. The increase in size will also have an impact on the clearance
of nanoparticles [76].
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C

Figure 3.5 (A) Stabilities of GUNW-3 DiR micelles and control DiR liposome in the
absence of FBS. (B) GUNW-3 DiR micelles stability in the presence of FBS. (C) control
DiR liposomes stability in the presence of serum. Data are presented as mean ±SD (n=3).
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3.3.6 Whole-body fluorescence imaging
In-vivo imaging of mice is a widely used method to investigate the in vivo brain
targeting ability of nanoparticles. DiR, a near infrared fluorescent lipophilic carbocyanine
and commonly used dye, is often encapsulated in nanoparticles to track the distribution of
nanoparticles in vivo. In this dissertation, DiR is encapsulated in GUNW-3 micelles
(GUNW-3 DiR micelles) to help track the distribution of GUNW-3 micelles in mice
through in vivo imaging. Additionally, DiR is a hydrophobic cationic molecule. The
abilities of GUNW-3 micelles to encapsulate DiR and to deliver DiR demonstrate the
ability of GUNW-3 micelles in delivering compounds with similar properties. In other
words, GUNW-3 DiR liposomes serve two purposes: i). help track the bio-distribution of
GUNW-3 micelles and determine if GUNW-3 micelles exhibit brain-targeting effects; ii).
demonstrate the ability of GUNW-3 to deliver DiR and DiR similar molecules. For a
comparison, control DiR liposomes and DiR dissolved in 5% ethanol (free DiR) were
employed as two controls. Since control DiR liposomes are cationic liposomes and
cationic liposomes have been reported to exhibit a brain targeting effect[73, 74, 76],
control DiR liposomes served as a good positive control. Since free DiR cannot pass
BBB, it was not expected to exhibit any brain target effects.
In the whole-body imaging experiment, mice were treated with GUNW-3 DiR
micelles, control DiR liposomes, or free DiR intravenously through tail vein injection.
Whole body imaging was performed at 15 min, 1 h, 24 h, and 48 h (Figure 3.6). As
demonstrated in Figure 3.6 C, GUNW-3 DiR micelles distributed to the brain rapidly
within 15 min. A minimum amount of control DiR liposomes were observed in the brain
(Figure 3.6.B) while no free DiR (Figure 3.6.A) was observed in the brain consistent with
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the literature report for the brain targeting ability of cationic liposomes and free DiR. The
fluorescence intensity remained strong for 48 h in the brain of the mouse treated with
GUNW-3 DiR micelles when compared with those from the control DiR liposomes and
free DiR suggesting a significant brain-targeting effect by GUNW-3 micelles. The brain
targeting of GUNW-3 micelles was further confirmed by the lateral images obtained at 1
h (Figure 3.7). As demonstrated in the lateral images, strong brain fluorescence was
observed for the mouse treated with GUNW-3 DiR micelles. The fluorescence was barely
visible in both brains of the mice treated with the control DiR liposomes and free DiR.
One interesting thing observed in the lateral images was that fluorescence was also seen
in the spinal cord of the mouse treated with GUNW-3 DiR micelles which further
confirms the entry of GUNW-3 DiR micelles into the CNS (Figure3.6. Lateral image).
Figure 3.7 shows the fluorescence intensity obtained from the brains of the wholebody images in Figure 3.6. The fluorescence intensity in the brain of the mouse treated
with GUNW-3 DiR micelles was 5.8 and 19 times higher than that from the control DiR
liposome and free DiR respectively. Interestingly, while both controls showed a decrease
in fluorescence intensity, GUNW-3 DiR micelles showed an increase in fluorescence
from 1 h to 48 h. At 48 h, the fluorescence intensity in the brain of the mouse treated with
GUNW-3 DiR micelles was 13 and 22 times higher than that from the control DiR
liposome and free DiR respectively (Figure 3.7).
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Figure 3. 6 In-vivo whole-body fluorescence imaging of mice at 15 min, 1 h, 24 h, and
48 h. A: Free DiR, B: Control DiR liposome, and C: GUNW-3 DiR micelles.
Representative image, n=3.
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Figure 3.7 Lateral image for each group at 1h. A: Free DiR, B: Control DiR liposome,
and C: GUNW-3 DiR micelles. Representative image, n=3.
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Figure 3.8 Fluorescence intensity from the brains of mice treated with GUNW-3 DiR
micelles, control DiR liposomes, or free DiR at different time points. Results are
presented as mean ± SEM (n=3).

72
3.3.7

Ex-vivo imaging.
To further confirm brain targeting, the brain and some of the other major organs

(brain, heart, lung, liver, spleen, and kidney) were collected for ex-vivo imaging at 1 h
and 48 h. Blood was removed by heart perfusion with DPBS before organ collection.
Fluorescence images of the organs were obtained using Xtreme in-vivo imaging (Bruker).
3.3.7.1 Ex-vivo brain imaging at 1 h
The fluorescence images of the collected brains at 1 h demonstrates that the
fluorescence intensity was significantly higher from the brain of the mouse treated with
GUNW-3 DiR micelles when compared with control DiR liposome and free DiR (p =
0.0002, one-way ANOVA with Tukey post-test, n=3) (Figure 3.8. A, B, C, D). Around 5fold of increase of the total fluoresce intensity in the brains of mice treated with GUNW3 micelles was observed when compared with the control DiR liposomes (p = 0.0006,
Tukey post-test) and 12-fold of increase when compared with free DiR (p =0.0003,
Tukey post-test) (Table 3.3). These ex-vivo results conclude that GUNW-3 micelles
exhibit a significant brain targeting effect.
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Figure 3.9 Ex-vivo imaging of the brains at 1 h after a single dose IV injection by tail
vein injection (0.250 mg/Kg DiR). A: Free DiR; B: Control DiR liposomes; C: GUNW-3
DiR micelles. D: Semi-quantitative fluorescence intensity of the brains (n=3, mean ±
SEM).
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Table 3 3 Comparison of fluorescence intensity from the brains of mice with different
treatments as presented in Figure 3.8
Comparison of brain fluorescence intensity

Statistical significance

Free DiR vs. control DiR liposomes

ns (p = 0.5268)

Free DiR vs. GUNW-3 DiR micelles

*** (p = 0.0003)

Control DiR liposome vs. GUNW-3 DiR micelles

*** (p = 0.0006)

ns: no statistically significant difference *˂0.05, **˂0.01, ***˂0.001, (n=3). One-way
ANOVA with a Tukey post-test was used to compare all three groups.
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3.3.7.2 Ex-vivo brain imaging at 48h
Ex-vivo brain imaging at 48 hours showed a 6.5-fold and 14-fold increase in
brain fluorescence from the mice treated with GUNW-3 DiR micelles when compared
with the control DiR liposomes (p = 0.0005, according to the Tukey post-test (Table 3.4))
and free DiR (p = 0.0003, according to the Tukey post-test ((Table 3.4) (Figure 3.9)).

Figure 3.10 Ex-vivo imaging of the brains at 48 h after a single dose IV injection by tail
vein injection (0.250 mg/Kg DiR). A: Free DiR; B: Control DiR liposomes; C: GUNW-3 DiR
micelles. D: Semi-quantitative fluorescence intensity of the brains (n=3, mean ± SEM).
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Table 3.4 Comparison of fluorescence intensity from the brains of mice with different
treatments as presented in Figure 3.9
Comparison of brain fluorescence intensity

Statistical significance

Free DiR vs. Control DiR Liposome

ns (p = 0.7185)

Free DiR vs. GUNW-3 DiR Micelles

***(p = 0.0003)

Control DiR Liposome vs. GUNW-3 DiR Micelles

***(p = 0.0005)

ns: no statistically significant difference *˂0.05, **˂0.01, ***˂0.001, (n=3). One-way
ANOVA with a Tukey post-test was used to compare all three groups,
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3.3.7.3 Ex-vivo tissue imaging at 1 h
In addition to brain distribution, tissue distribution in other major organs (heart,
lung, liver, spleen, and kidney) at 1 h was investigated. The results are presented in
Figure 3.10. As shown in the figure, GUNW-3 micelles appear to distribute to the heart,
lungs, liver, and kidneys with a high accumulation in the liver. The control DiR
liposomes also distributed to the heart, lungs, liver and kidneys with a high accumulation
in the lungs while free DiR distributed mainly to the lungs and liver with a high
accumulation in the lungs. The total fluorescence intensity from the collected organs
appears to be strongest from the mouse treated with GUNW-3 DiR micelles, followed by
that from the control DiR liposomes, and then that from free DiR. The observed organ
distribution differences from these three formulations appear to be in line with the
particle size as reported in the literature. Several studies have shown that the size of the
nanoparticle significantly affects organs distribution and smaller nanoparticles (less than
30 nm) were more favored in organ distribution [77].
One of the other possibilities that may contribute to the organ distribution
difference could be from the different clearance rates of these formulations. A
pharmacokinetic study is needed to further provide insights.
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Figure 3.11 Ex-vivo imaging of the major organs collected 1 h after a single dose IV
injection (0.250 mg/Kg DiR) of A: free DiR, B: control DiR liposome, and C: GUNW-3
DiR micelles. Organs (H: heart, Lu: lung, Li: liver, S: spleen, and K: kidney) were
collected after heart perfusion with DPBS to remove blood in tissues, D: Semiquantitative fluorescence intensity of different organs (n=3, mean ± SEM).
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Table 3.5 Comparison of fluorescence intensity from the brains of mice with different
treatments as presented in Figure 3.11

Free DiR vs. Control
DiR Liposome
Free DiR vs. GUNW3 DiR Micelles
Control DiR
Liposome vs. GUNW3 DiR Micelles

Heart
ns
(0.9984)
ns
(0.2789)
ns
(0.2979)

Lung
ns
(0.953)
ns
(0.2587)
Ns
(0.1786)

Liver
ns
(0.923)
*
(0.0116)
**
(0.078)

Kidney
ns
(0.9244)
***
(0.0004)
***
(0.0005)

Spleen
ns
(0.2506)
ns
(0.2355)
*
(0.0255)

ns: no statistically significant difference, *˂0.05, **˂0.01, ***˂0.001, (n=3). One-way
ANOVA with a Tukey post-test was used to compare all three groups
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3.3.7.4 Ex-vivo tissue imaging at 48 h
Tissue distribution in other major organs at 48 h was also examined (Figure 3.11).
It appears that significant accumulation was still observed at 48 h in the liver for mice
treated with GUNW-3 DiR micelles and control DiR liposomes. The liver from mice
treated with GUNW-3 DiR micelles showed much stronger fluorescence intensity than
that with the control DiR liposomes. The total fluorescence intensity from the organs
collected was strongest from the mice treated with GUNW-3 DiR micelles, followed by
control DiR liposomes, then free DiR – the same trend as observed at 1 h. This trend
appears to be consistent with the possibility that GUNW-3 DiR micelles being retained in
mice longer than control DiR liposomes and free DiR. This might have occurred due to a
stronger interaction of GUNW-3 with BSA as observed in section 3.5.5.2 and was
consistent with the knowledge that conjugation with albumin increased the serum halflife of the nanoparticles [78]. Again, a pharmacokinetic study is needed to provide more
insights on this.
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Figure 3.12 Ex-vivo imaging of the major organs 48 h after a single dose IV injection
(0.250 mg/Kg DiR) of A: Free DiR, B: control DiR liposome, and C: GUNW-3 DiR
micelles. Organs (H: heart, Lu: lung, Li: liver, S: spleen, and K: kidney) were collected
after heart perfusion with DPBS to remove blood in tissues. D: Semi-quantitative
fluorescence intensity of different organs (n=3, mean ± SEM).
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Table 3.6 Comparison of fluorescence intensity from the brains of mice with different
treatments as presented in Figure 3.12

Free DiR vs.
Control DiR
Liposome
Free DiR vs.
GUNW-3
DiR Micelles
Control DiR
Liposome vs.
GUNW-3
DiR Micelles

Heart
ns
(0.2326)

Lung
ns
(0.9547)

Liver
ns
(0.1476)

Kidney
ns
(0.4447)

Spleen
ns
(0.9994)

**
(0.0018)

ns
(0.3535)

**
(0.0012)

*
(0.0173)

ns
(0.9931)

*
(0.0101)

ns
(0.2491)

**
(0.0091)

ns
(0.0824)

ns
(0.9965)

ns: no statistically significant difference *˂0.05, **˂0.01, ***˂0.001, (n=3). One-way
ANOVA with a Tukey post-test was used to compare all three groups,
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In summary, GUNW-3 is an amphiphilic compound that can form micelles. Its
low CMC value (3.9 μM) suggests that GUNW-3 micelles are stable enough to be used
as a drug delivery system for a therapeutic application. We also demonstrate that GUNW3 micelles were stable in the stock solution for 5 days at 4 °C and exhibited a better
stability in the presence of FBS at 37 °C when compared with the control liposomes.
Most importantly, we demonstrate that the brain uptake of GUNW-3 DiR micelles were
5-times higher than that of the control DiR liposome and 12-times higher than that of free
DiR at 1 h after a single dosage IV injection. At 48 h after a single dosage IV injection,
the brain uptake of GUNW-3 micelles was 6.5 times higher than that of control DiR
liposomes and 14 times higher than that of free DiR. Our data provide a proof of concept
for potential application of GUNW-3 micelles as an effective drug delivery system for
delivering therapeutic and preventive agents to the brain for the treatment and prevention
of brain diseases.
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Chapter 4
4.1

Brain-Targeting of GUNW-3 Liposomes

Introduction
Liposome is a word that originally derives from two Greek words: lipo (fat) and

soma (body)[79]. Liposomes are well established and widely used nanoparticles for drug
delivery [80, 81]. A search for liposomes in PubMed reveals more than 48,000 results as
of today. There are around 40 liposomal formulations in clinical studies and more than 12
liposomal products in the market worldwide [34]. Structurally, a liposome consists of an
aqueous core surrounded by a bilayer of natural or synthetic lipids (Figure4.1).
Liposomes can encapsulate various molecules: small, large, hydrophilic,
hydrophobic, and biologicals like peptides, proteins, DNA, and RNA without any
modification to these molecules [76]. Liposomes deliver compounds with hydrophilic
molecules being carried within the aqueous core and hydrophobic molecules being
carried within the hydrophobic double lipid layers (Figure 4.1). Liposomes can also be
modified for targeted delivery by coating the liposome surface with a targeting molecule
to take the liposomes to a disease site such as cancer or to a tissue such as the brain
(Figure 4.1).
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Figure 4.1 A graphic description of a liposome[82].
4.1.1

Classification of liposomes
Liposomes can be classified based on their composition, delivery mechanism,

structural property, surface charge, and preparation methods [83]. A brief description of
these classifications is presented below.
A. Based on the intracellular delivery mechanism that usually depends on its
composition, liposomes can be classified into: (i). conventional liposomes;
(ii). immune liposomes; (iii). long circulation liposomes; (iv). pH-sensitive
liposomes; (v). charge liposomes; and (vi) fusogenic liposomes.
B. Based on the property of the stretcher, liposomes can be divided into: (i).
Multilamellar vesicles with a particle size >0.5 μm (MLV); (ii). Oligolamellar
vesicles with a particle size of 0.1-1 μm (OLV); (iii). Unilamellar vesicles
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(ULV); (iv). Small unilamellar vesicles with a particle size of 20-100 mm
(SUV); (v) Medium size unilamellar vesicles (MUV); (vi). Large unilamellar
vesicles with a particle size >100 mm; (vii). Giant unilamellar vesicles with a
particle size >1 μm (GUV); and (viii). Multivesicular vesicles with a particle
size > 1 μm (MVV).
C. Based on surface charge, liposomes can be divided into positively charge
liposomes (cationic liposomes), negatively charge liposomes (anionic
liposome), and neutral liposomes. Liposomes surface charge (zeta potential) is
dependent on the lipid composition used in preparing the liposomes.
D. Based on the method of preparation, liposomes can be prepared by: (i).
Reverse-phase (REV); (ii). Frozen and Thawed MLV (FATMLV); (iii).
Extrusion method (VET); (iv) French press (FPV); (v). Fusion method (FUV);
and (vi). Dehydration-rehydration method (DRV).
4.1.2

Liposomes for brain targeting
Liposomes have been used to improve drug accumulation in the brain, especially

positively charged liposomes which have been found to increase brain penetration by
adoptive-mediated endocytosis due to an electrostatic interaction between the positively
charged liposomes and negatively charged cell membrane [73, 74, 76]. However, even
positively charged liposomes had a limited ability to pass the blood brain barrier (BBB) if
the liposomes contain no brain-targeting ligand[34] . Thus, the coating liposome surface
with a brain-targeting ligand is a common approach in improving the brain targeting
ability of liposomes [34]. Effective brain-targeting ligands have been found to be those
substrates of a receptor or transporter that is highly expressed in the BBB. These
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substrates include glucose, amino acids, transferrin, insulin, low density lipoprotein, and
glutathione (GSH) etc [44, 84]. The first work to improve the brain-targeting ability of
liposomes by coating its surface with a brain targeting ligand was reported in 1996 and
the brain-targeting agent was transferrin [38]. GSH is a relatively recent brain targeting
agent.
4.1.3

GUNW-3 liposomes for brain targeting
In this investigation, we studied the improvement of brain-targeting of a cationic

liposome by GUNW-3 – GUNW-3 liposomes. GUNW-3 liposomes are expected to be
formed by imbedding the hydrophobic cholesterol moiety of GUNW-3 into the double
lipid layer of the liposomes and the hydrophilic GSH part floating on the surface of the
liposome for brain targeting. The reason for selecting cationic liposomes was based on
the fact the cationic liposomes exhibit certain brain-targeting effects.
GUNW-3 liposomes are made up of lecithin, cholesterol, dimethyldoioctadecylammonium bromide (DDAB), and GUNW-3. Below is a brief description of these
components.
A. Lecithin
Soy lecithin is a phospholipid and is the main part of liposomes. A phospholipid
is an amphiphilic molecule with a hydrophilic group located at one end of the molecule
and a hydrophobic group located at the other end (Figure 4.2). The hydrophilic phosphate
group of the phospholipid is negatively charged. When the phospholipid is hydrated,
molecules of phospholipid arrange themselves to a structural bilayer forced by Van-der
Waals, hydrophilic, and hydrophobic interactions [85].
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Figure 4.2 Chemical structure of Lecithin.

B. Cholesterol
Cholesterol helps decrease the fluidity of the lipid bilayer and increases the
stability of liposomes in the biological system (Figure 4.3) [86].

Figure 4.3 Chemical structure of cholesterol

C. DDAB
Dimethyldoioctadecylammonium bromide (DDAB) is a cationic lipid. Along with
the negatively charged lecithin, DDAB helps increase interlamellar resistance between
successive bilayers (Figure 4.4). This effect will result in an overall entrapped
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volume[87]. Moreover, DDAB helps generate the positively charged liposomes that helps
improve brain uptake when compared with neutral or anionic liposomes [73, 74, 76].

Figure 4.4 Chemical structure of dimethyldoioctadecylammonium bromide (DDAB)

D. GUNW-3
GUNW-3 is a glutathione transporter-based brain-targeting agent designed and
synthesized by us (Figure 4.5). The synthetic procedure of GUNW-3 was described in
chapter 2 of this dissertation. Insertion of GUNW-3 to the liposome surface is expected to
improve brain-targeting of liposomes.

Figure 4.5 Chemical structure of GUNW-3

By using the whole-body imaging technique and DiR as a tracking agent to track
distribution, we have demonstrated that GUNW-3 liposomes quickly distributed into the
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brain and significantly increase the brain distribution when compared with control
liposomes (the cationic liposomes). Ex-vivo imaging of the collected brains showed a 3fold increase in brain distribution of GUNW-3 liposomes when compared with control
liposomes. Our data from this project confirm the ability of GUNW-3 to improve the
brain-targeting ability of liposomes.
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4.2

Experimental section

4.2.1

Material and instruments
Unless otherwise stated, all chemical reagents and solvents were obtained from

commercial sources and used without further purification. GUNW-3 was synthesized
based on the procedure presented in Chapter 2. Lecithin (Phospholipon 90G) was
obtained from Lipoid (Ludwigshafen, Germany), cholesterol from MP biomedicals
(solon, OH, USA), DDAB from Applichem (Darmstadt, Germany), DiR from Fisher
Scientific (Pittsburgh, PA, USA), filter paper, filter support, and extrusion apparatus from
Avanti Polar Lipid, Inc (Alabaster, Al, USA), Sephadex columns ( PD10 column) from
GE health care (Little Chalfont, UK). PRMI 1640 growth medium,
penicillin/streptomycin, phosphate buffered saline (PBS), trypsin, and fetal bovine serum
(FBS) were obtained from Mediatech (Herndon, VA). , Dulbecco’s phosphate buffered
saline (Gicob™D DPBS, no calcium, no magnesium,1x) was purchased from Thermo
Fisher Scientific (Waltham, MA, USA). In-vivo and ex-vivo imaging was obtained on a
Xtreme in-vivo imaging (Bruker).
4.2.2

Procedures

4.2.2.1 DiR liposomes
Both GUNW-3 DiR liposomes and control DiR liposomes were prepared by using
the Thin Layer Hydration technique. Briefly, Lecithin (7 mg/ml), cholesterol (1 mg/ml),
DDAB (2 mg/ml), and DiR (0.025 mg/ml) were dissolved in chloroform. To form a thin
film, solvents were evaporated by rotavapory evaporation overnight under a reduced
pressure. The thin film was hydrated with a DPBS solution for control DiR liposomes or
a DPBS solution with GUNW-3 (7 mg/mL) for GUNW-3 DiR liposome for 10 min
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followed by vortexing for 2 min. To obtain the desired size, a bath sonicator was
employed to sonicate the mixture for 20 min (4 min sonication with 1 min break)
followed by extrusion with a 200 nm then 100 nm filter. A Sephadex column (PD 10
column, GE health care, Little Chalfont, UK) was used to remove untrapped DiR by
centrifugation (2500rpm for 2 min) to give the control DiR liposomes or GUNW-3 DiR
liposomes.
The liposomes were diluted (0.5:100) with deionized water before used for
particle size and zeta potential determination using the dynamic light scattering (DLS)
method on a Zetasizer (Malvern instrument, Westborough, MA).
4.2.2.2

Determination of the encapsulation efficiency (EE%) and loading

capacity (LC%) of DiR liposomes
The EE% and LC% of GUNW-3 DiR liposomes and control DiR liposomes were
determined by the fluorescence intensity of DiR. GUNW-3 DiR liposomes or control DiR
liposomes were dissolved in DMSO to a concentration of 7 mg/ml. The GUNW-3
liposomes solution or control liposomes solution (60 μl) and DMSO (40 μl) were pipetted
into a well of a 96-well plate for fluorescence intensity measurement on a fluorescent
plate reader by using 730 nm and 780 nm as the excitation and emission wavelengths. A
calibration curve was constructed by spiking a known concentration of DiR to a blank
liposomes in DMSO[72].
4.2.2.3

Liposomes stability study
The storage stability of liposomes was studies at 4 °C – the storage temperature.

Since liposomes will encounter proteins once in the blood circulation, the stability of
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liposomes in the presence of proteins (FBS) was investigated at 37 °C. The particle size
was used as a parameter for micelle stability studies.
4.2.2.3.1

Stabilities of GUNW-3 DiR liposomes and control DiR liposomes

The particle size of a freshly prepared GUNW-3 DiR liposomes and control
liposomes were checked, after a 0.5:100 dilution with deionized water as described early,
every 24 h at 4°C for 7 days. The size was checked by the dynamic light scattering (DLS)
method using Zetasizer (Malvern instrument, Westborough, MA).
4.2.2.3.2

Stabilities of GUNW-3 DiR liposomes and control DiR liposomes in

the presence of FBS
Using the partial size as an indicator, the stability of GUNW-3 DiR liposomes (1
mg/mL) and control DiR liposome (1 mg/mL) were checked in the presence of RPMI
1640 growth medium supplemented with 10% FBS at 37 °C. Samples were diluted to a
concentration of 0.5:100 with deionized water and the size was checked by the dynamic
light scattering (DLS) method using Zetasizer (Malvern instrument, Westborough, MA).
4.2.2.4 Whole body optical imaging of mice
Females BALB/Cj mice (6-8 weeks old, 17-20 g) were used for this work. Mice
were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and acclimatized to a
laboratory condition for one week before the experiment. For the experiment, mice were
divided into two groups and intravenously injected with GUNW-3 DiR liposomes and
control DiR liposomes (250 µg DiR/Kg) respectively through the tail vein. Optical
images for the whole body were taken at 5 min, 15 min, 30 min, 60 min, and 180 min.
The images were analyzed using the Bruker MI SE software. All procedures were
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approved by the Institutional Animal Care and Use Committee (IACUC) at South Dakota
State University, Brookings, SD, USA.
4.2.2.5 EX-vivo brain and organ imaging
To assess the organ distribution, mice were sacrificed 1 h and 48 h after a single
dose IV injection by the tail vein injection The heart was perfused with DPBS to remove
blood before organs were collected. The images were using the Bruker MI SE software.
4.2.2.6

Statistics
In this work, results from in vitro experiments were reported as mean ± standard

deviation (SD) and results from in vivo experiment were reported as standard error of
mean (SEM). Student’s t-test was used to compare two groups. The results reported using
GraphPad Prism 8 to demonstrate the statistical difference (p ˂ 0.05).
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4.3

Result and Discussion

4.3.1

Liposome preparation
Control and GUNW-3 liposomes were prepared based on the thin layer hydration

method. Lecithin, DDAB, and cholesterol, and DiR were added to chloroform. The
chloroform was evaporated to from the lipid film. The lipid film was hydrated with
DPBS with or without GUNW-3 to form GUNW-3 DiR liposomes or control DiR
liposomes. A graphic description of the procedures is presented in Figure 4.6.

Figure 4.6 Graphic description of the preparation of GUNW-3 DiR liposomes and control
DiR liposomes using the thin hydration method.
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4.3.2 Characterization of DiR liposomes
The average particle size and size distribution of the control DiR liposomes and
GUNW-3 DiR liposomes are presented in Figure 4.7. The particle size of the control DiR
liposomes and GUNW-3 DiR liposomes was found to be 99.56 nm ± 2.5 and 102.3 nm ±
0.6 respectively. The parameter for the size distribution (PDI) for control DiR liposomes
and GUNW-3 DiR liposomes were 0.205 and 0.228 respectively (Figure 4.6.B, Table
4.1). The zeta potential of the control DiR liposomes and GUNW-3 DiR liposomes were
+19.2 mV ± 6.53 and -27.4mV ±1.6 (Figure 4.7.B). It is noted that the charge of the
liposomes changed from positive (control DiR liposomes) to negative (GUNW-3 DiR
liposomes) after the liposomes were added with GUNW-3. The negative charge on the
GUNW-3 DiR liposome surface was a result of negative charges from the GUNW-3
molecule. A change of the surface charge of the liposomes is an indication that the
liposome surface is now containing the brain targeting molecule GUNW-3.
The EE% and LC% of the control DiR liposomes were 69% ±0.7 and 0.17%
while the EE% and LC% of GUNW-3 DiR liposomes were 71±0.5% and 0.16%
respectively (Table 4.1). Both liposomes contained the same amount of phospholipid (7
mg/ml), cholesterol (1 mg/ml), and cationic lipid (DDAB) (3mg/ml). GUNW-3 was
determined to be 4.48 mg/mL by LC/MS.
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Figure 4.7 Particle size and size distribution of control DiR liposomes (A), and GUNW-3
DiR liposome (B).
Table 4.1 Parameters of control DiR liposomes and GUNW-3 liposomes (n = 3, mean
±SD).
Formulation

Theoretical
loading (%)

Size (nm)

Control DiR
liposomes

0.25

99.5 ±
2.5

GUNW-3 DiR
liposomes

0.22

102 ± 0.6

PDI

Zeta
potential
(mV)
0.205 +19.2 ±6.5

EE%

LC%

69 ± 0.7

0.17 ±
0.0013

0.288 -27.4±1.9

71 ± 0.5

0.16 ±
0.0008
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4.3.2

Liposome stability

4.3.2.1 DiR liposome storage stability
The storage stabilities of GUNW-3 DiR liposomes and control DiR liposomes
were monitored at 4 °C for 7 days and the results are presented in Figure 4.8A. The
particle size was the parameters used to determine the stability. The size of the control
DiR liposomes was 99.56 ± 2.89 nm on day 1 compared with 102.83 ± 1.2 nm on day 7,
no statistical difference was found on day 1 and day 7. The same was true with GUNW-3
DiR liposomes: particle size was 102 ± 0.6 nm on day 1 vs 96 ± 1.6 nm on day 7 with no
statistical difference. These results suggest that both liposomes were stable at its storage
temperature for 7 days.
4.3.2.2 Stability of DiR liposome in the presence of proteins (FBS)
The stability of GUNW-3 DiR liposomes and control DiR liposomes were studied
in RPMI 1640 growth medium supplemented with 10% FBS. The results are presented in
Figure 4.8 B, and C). GUNW-3 DiR liposomes increased the size from 127 nm to 250 nm
in the first hour while control DiR liposomes increased the size from 124 nm to 358 nm
in the first hour. Similar to GUNW-3 DiR micelles, GUNW-3 DiR liposomes then
appeared to slowly and continuously increase its size to 389 nm by 48 hours
demonstrating a two-phase increase in particle size while control DiR liposomes
remained almost unchanged. As we suggested in GUNW-3 DiR micelles, this two-phase
increase in particle size indicates possibly two different mechanisms in particle size
increases. One possible explanation might be that GUNW-3 liposomes may quickly
complex with FBS that quickly increased the particle size initially (first phase size

99
increase), then followed by a slow increase in particle size which might be caused by
particle aggregation.

Figure 4.8 Stability of GUNW-3 DiR liposomes and control DiR liposomes. A: storage
stability at 4 C for 7 days; B: GUNW-3 DiR liposomes; C: Control DiR liposomes
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stability in the presence of proteins (FBS) at 37 C for 7 days. Results are presented as
mean ±SD (n = 3).
4.3.3

In-vivo imaging
Whole body imaging of the mice treated with GUNW-3 DiR liposomes or control

DiR liposomes was conducted to investigate the brain targeting effect of GUNW-3 DiR
liposomes. Mice were treated with GUNW-3 DiR liposomes or control DiR liposomes
with a single dose IV injection (0.25 mg/kg DiR) by the tail vein injection. Whole body
images were taken at 15 min, 30 min, 60 min, and 180 min (Figure 4.11). In-vivo
imaging showed a fast brain distribution (15 min) for GUNW-3 DiR liposomes while
control DiR liposomes showed a fast liver distribution. Control DiR liposomes also
showed a minimum brain distribution (Figure 4.9) which is consistent with the
knowledge that cationic liposomes exhibit some brain-targeting effects. The fluorescence
intensity in the brain continued to grow for GUNW-3 DiR liposomes till 30 min and
maintained the same intensity till 60 min then started to drop (Figure 4.9). The
fluorescence intensity from the brain treated with control DiR liposomes appeared to
increase till 30 min then remain unchanged for the rest of the experiment (180 min). The
increase in brain targeting based on the brain fluorescence intensity are 23 times at 15
min and 9 times at 30 min (Figure 4.10).
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Figure 4.9 In-vivo whole-body imaging of mice at 15 min, 30 min, 60 min, and 180 min.
A: control DiR liposomes; and B: GUNW-3 DiR liposomes. Representative image, n=3.
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Figure 4.10 In-vivo semi-quantitative fluorescence intensity of brains. Results are
presented as mean ± SEM (n=4).
4.3.4

Ex-vivo imaging.
To further confirm brain targeting, brain and some of the other major organs

(brain, heart, lung, liver, spleen, and kidney) were collected for ex-vivo imaging at 1 h.
Blood was removed by hear perfusion with DPBS before organ collection. Fluorescence
images of the organs were obtained using Xtreme in-vivo imaging (Bruker).
4.3.4.1 Ex-vivo brain imaging at 1 h
As shown in figure 4.11. A and B, a significant increase in brain distribution was
observed with mice treated with GUNW-3 DiR liposomes when compared with that from
the control DiR liposomes (Figure 4.11). Based on the fluorescence intensity, GUNW-3
DiR showed a 3-times brain distribution when compared with the control liposomes
(p=0.0443, n=3, Figure 4.11. C). The results suggested that GUNW-3 liposomes exhibit a
significantly high brain targeting ability than control DiR liposomes.
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Figure 4 11 Ex-vivo imaging of the brains at 1 h after a single dose IV injection of A:
control DiR liposomes or B: GUNW-3 DiR liposomes. D: Semi-quantitative fluorescence
intensity of brains presented as mean ± SEM. *˂0.05, **˂0.01, ***˂0.001 (n = 3).
4.3.4.2 Ex-vivo organ imaging at 1 h
In addition to brain distribution, distribution to other major organs (heart, lung,
liver, spleen, and kidney) was examined. The images of these organs and their
corresponding fluorescence intensities were presented in Figure 4.12 and Figure 4.13.
Based on the fluorescence intensity in Figure 4.13, it appears the major distribution of
both liposomes was in the liver and lung though distribution in the heart, kidney and
spleen was also observed. It appeared control DiR liposomes distributed to the liver and
lungs more than GUNW-3 DiR liposomes while GUNW-3 DiR liposomes distributed to
the kidney more than control DiR liposomes. The higher organ distribution of the control
DiR liposomes comparing to GUNW-3 DiR liposomes may be explained by the
interaction between the GUNW-3 DiR liposomes to albumin which decreases the
distribution of GUNW-3 DiR liposomes to organs. This interaction happens because of
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the presence of GSH on the surface of GUNW-3 liposomes. It has been reported that
GSH can bind to BSA at site I in subdomain IIA according to the molecular docking
results. The binding process is dominated by hydrogen bonds, which is consistent with
the fluorescence studies. It was concluded that there was a strong interaction between
GSH and BSA. The binding of a drug to albumin is believed to reduce the level of free
drug available [88-90].
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A

B

Figure 4.12 Ex-vivo imaging of the major organ 1h after (i.v) injection of the (A) Control
DiR liposomes (B) GUNW-3 DiR liposomes. Organs (H: heart, Lu: lung, Li: liver, S:
spleen, and K: kidney). Representative image, n=3.
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Figure 4.13 Semi-quantitative fluorescence intensity from different organs. Data were
presented as mean ± SEM, ns: no statistically significant difference, *˂0.05, **˂0.01,
***˂0.001 (n = 3).
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In summary, we have demonstrated that GUNW-3 liposomes were able to
encapsulate DiR and deliver DiR to the brain. Ex-vivo imaging showed GUNW-3 DiR
liposomes reached the brain 3 times of control DiR liposomes. Our data show that
GUNW-3 liposomes have the potential to be developed into an effective drug delivery
system for brain-targeting.
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Chapter 5.

Conclusion, Significance, and Future Direction

5.1 Conclusion
The BBB is a selective barrier made by endothelial cells that separates the
peripheral blood circulation from the CNS. The BBB serves as a physical barrier through
the tight junction of endothelial cells and overdistribution of different drug efflux pumps
such as P-glycoproteins and multidrug-resistance protein. Because of that reason, nearly
all big drug molecules and more than 98% of small drug molecules are not able to reach
the brain to effectively treat brain diseases. Utilizing endogenous ligands of receptors or
transporters that are expressed on the surface of the BBB is one of the most commonly
employed methods to overcome the BBB issue. GSH is found in both endothelium cells
and astroglia with mM concentration. GSH transporters are highly expressed on the BBB
surface.
This dissertation presented a rational design and synthesis of GSH-based brain
targeting molecule, GUNW-3. GUNW-3 was designed to contain a GSH molecule as a
hydrophilic head group and a cholesterol molecule as a hydrophobic tail group. These
two groups are connected with a small linker of a diethylene glycol group. As an
amphiphilic molecule, GUNW-3 can form micelles by itself. Micelles are an effective
drug delivery system. GUNW-3 micelles were expected to be brain targeting due to the
presence of the hydrophilic GSH part on the surface of the micelles. Moreover, we used
GUNW-3 to modify the liposome surface to to form GUNW-3 liposomes for brain
targeting.
Ex-vivo brain targeting evaluation of GUNW-3 micelles showed 5-times higher
in brain targeting than that of the control liposomes and 12-times higher than that of free
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DiR at the first hour after an i.v dosing. Forty eight hours post dosing, GUNW-3 micelles
showed 6.5 times higher in brain targeting than that of control liposome and 14 times
higher than that of free DiR. Our data confirm the ability of the brain delivery of the
GUNW-3 micelles. Brain targeting was also observed with GUNW-3 liposomes. Ex-vivo
imaging of the brains showed a 3 times increase in brain targeting by GUNW-3
liposomes when compared with the control liposomes.
In summary, we have successfully synthesized and characterized the rationally
designed GUNW-3 as a brain targeting agent. GUNW-3 micelles and GUNW-3
liposomes are promising drug delivery systems for delivering therapeutic and diagnostic
agents to the brain for therapeutic, preventive, and diagnostic applications.

5.2 Limitation
This work focuses on confirming the brain-targeting ability of GUNW-3 as a
micelle (GUNW-3 micelles) or as a brain-targeting agent to facilitate liposomes to cross
the BBB. The abilities of GUNW-3 to improve brain targeting of both formulations
(micelles and liposomes) were confirmed by using DiR as a tracking agent. DiR is very
widely used dye to confirm the in vivo distribution of nanoparticles. However, drugs with
different lipophilicities are needed to determine the applicability of these two
formulations. Further, an in vitro experiment with brain endothelial cells need to be
conducted to confirm that these two formulations enter the cells through the GSH
transporter.
5.3 Significance
The BBB is the major cause of treatment failure for various brain diseases such as
brain cancer and caner metastasis, Parkinson’s disease, and Alzheimer’s disease etc. The
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failure is resulted from the inability of a drug molecule to pass the BBB to achieve the
effective therapeutic concentration. This dissertation demonstrates a proof of concept that
both GUNW-3 micelles and GUNW-3 liposomes can effectively deliver molecules to the
brain. The preliminary data also show that GUNW-3 micelles and GUNW-3 liposomes
are not cytotoxic at the dosages employed both in vitro and in vivo. GUNW-3 micelles
and GUNW-3 liposomes may find a great application in helping treatment of various
brain diseases.
5.4 Future direction
GUNW-3 micelles and GUNW-3 liposomes showed a promising brain targeting
ability. Our future plan for this project includes:
•

Further characterization GUNW-3 liposomes and micelles
•

In vitro mechanistic study of brain-targeting

•

In vivo pharmacokinetics study

•

Evaluation of GUNW-3 micelles and GUNW-3 liposomes to encapsulate
therapeutic and diagnostic compounds.

•

Prepare more GUNW-3 derivatives for more effective brain targeting agents.
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